Gefitinib (ZD1839)

Name: Gefitinib (ZD1839)
Brand: Selleck Chemicals
SKU: S1025
Rating: 5 (499 reviews)

For research use only.

Catalog No.S1025 Synonyms: Iressa

499 publications

CAS No. 184475-35-2

Gefitinib (ZD-1839, Iressa) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively. Gefitinib promotes autophagy and apoptosis of lung cancer cells via blockade of the PI3K/AKT/mTOR pathway.

Selleck's Gefitinib (ZD1839) has been cited by 499 publications

Nat Cell Biol, 2021, 23(4):377-390

PubMed: 33795873 ( click the link to review the publication )

Cell Stem Cell, 2020, 7;26(5):782-792e7

PubMed: 32348727 ( click the link to review the publication )

Cancer Cell, 2020, 13;37(1):104-122e12

PubMed: 31935369 ( click the link to review the publication )

Cancer Discov, 2019, 9(7):926-943

PubMed: 31092401 ( click the link to review the publication )

Cell Stem Cell, 2019, 25(1):69-86

PubMed: 31080136 ( click the link to review the publication )

Cell, 2018, 172(1-2):373-386

PubMed: 29224780 ( click the link to review the publication )

Nat Med, 2018, 24(4):512-517

PubMed: 29505033 ( click the link to review the publication )

Nat Methods, 2018, 15(8):631-639

PubMed: 30038414 ( click the link to review the publication )

Cancer Cell, 2018, 34(3):427-438

PubMed: 30205045 ( click the link to review the publication )

Nature, 2017, 547(7664):453-457

PubMed: 28678785 ( click the link to review the publication )

Nature, 2016, 30;534(7609):647-51.

PubMed: 27338794 ( click the link to review the publication )

Nat Med, 2016, 22(3):262-9

PubMed: 26828195 ( click the link to review the publication )

Cancer Discov, 2015, 5(7):713-22

PubMed: 25934077 ( click the link to review the publication )

Cancer Discov, 2015, 5(9):960-971

PubMed: 26036643 ( click the link to review the publication )

Nature, 2014, 3;508(7494):118-22.

PubMed: 24670642 ( click the link to review the publication )

Nat Med, 2013, 19(11):1469-1472

PubMed: 24162815 ( click the link to review the publication )

Nature, 2012, 26;483(7387):100-3.

PubMed: 22281684 ( click the link to review the publication )

Cell, 2012, 21;151(5):937-50.

PubMed: 23178117 ( click the link to review the publication )

Cancer Discov, 2012, 2(10):934-47

PubMed: 22961667 ( click the link to review the publication )

Cancer Discov, 2011, 1(7):608-25

PubMed: 22586683 ( click the link to review the publication )

Theranostics, 2021, 11(2):824-840

PubMed: 33391507 ( click the link to review the publication )

Theranostics, 2021, 11(6):2594-2611

PubMed: 33456562 ( click the link to review the publication )

Mol Cancer, 2021, 20(1):17

PubMed: 33461557 ( click the link to review the publication )

Cancers (Basel), 2021, 13(2)E272

PubMed: 33450879 ( click the link to review the publication )
Cancers (Basel), 2021, 13(6)1198

PubMed: 33801941 ( click the link to review the publication )

PLoS Pathog, 2021, 17(1):e1009221

PubMed: 33471869 ( click the link to review the publication )

Cell Death Dis, 2021, 12(1):83

PubMed: 33446634 ( click the link to review the publication )

J Clin Endocrinol Metab, 2021, dgab020

PubMed: 33524147 ( click the link to review the publication )

Transl Lung Cancer Res, 2021, 10(3):1277-1291

PubMed: 33889509 ( click the link to review the publication )

Biochim Biophys Acta Mol Cell Res, 2021, 1868(6):119016

PubMed: 33744274 ( click the link to review the publication )

Sci Rep, 2021, 11(1):7259

PubMed: 33790333 ( click the link to review the publication )

Drug Metab Dispos, 2021, 49(1):53-61

PubMed: 33148688 ( click the link to review the publication )

Environ Toxicol, 2021, 10.1002/tox.23125

PubMed: 33734566 ( click the link to review the publication )

Oncol Lett, 2021, 21(5):418

PubMed: 33841579 ( click the link to review the publication )

Transl Lung Cancer Res, 2021, 10(1):128-142

PubMed: 33569299 ( click the link to review the publication )

Sci Total Environ, 2021, 775:145814

PubMed: 33621883 ( click the link to review the publication )

FASEB J, 2021, 35(3):e21393

PubMed: 33570794 ( click the link to review the publication )

Toxicol Lett, 2021, S0378-4274(21)00043-6

PubMed: 33571620 ( click the link to review the publication )

Acta Neuropathol, 2020, 17

PubMed: 32303840 ( click the link to review the publication )

Acta Neuropathol, 2020, 10.1007/s00401-020-02226-7

PubMed: 33009951 ( click the link to review the publication )

Nat Commun, 2020, 21;11(1):1923

PubMed: 32317663 ( click the link to review the publication )

Nat Commun, 2020, 11(1):4607

PubMed: 32929081 ( click the link to review the publication )

Nat Commun, 2020, 25;11(1):1556

PubMed: 32214092 ( click the link to review the publication )

Sci Adv, 2020, 6(11):eaax2271

PubMed: 32195335 ( click the link to review the publication )

EMBO Mol Med, 2020, 12(8):e11987

PubMed: 32672423 ( click the link to review the publication )

Clin Cancer Res, 2020, clincanres.3555.2020

PubMed: 33355298 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432

PubMed: 32034078 ( click the link to review the publication )

EMBO Mol Med, 2020, 12(8):e11987

PubMed: 32672423 ( click the link to review the publication )
Mol Syst Biol, 2020, 16(2):e8664

PubMed: 32073727 ( click the link to review the publication )

Cancer Res, 2020, 80(22):4998-5010

PubMed: 33023947 ( click the link to review the publication )

Aging Cell, 2020, 22:e13145

PubMed: 32323422 ( click the link to review the publication )

Elife, 2020, 9e60541

PubMed: 32940599 ( click the link to review the publication )

Redox Biol, 2020, 38:101780

PubMed: 33171331 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-01465-y

PubMed: 32978523 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-01497-4

PubMed: 33037411 ( click the link to review the publication )

Cancer Lett, 2020, 475:109-118

PubMed: 32004572 ( click the link to review the publication )

Sci Signal, 2020, 3;13(621) pii: eaax2364

PubMed: 32127496 ( click the link to review the publication )

Cancers (Basel), 2020, 12(12)E3761

PubMed: 33327495 ( click the link to review the publication )

Cancers (Basel), 2020, 27;12(5)pii: E1087

PubMed: 32349331 ( click the link to review the publication )

Cancers (Basel), 2020, 13;12(2) pii: E436

PubMed: 32069833 ( click the link to review the publication )

Cancers (Basel), 2020, 12(2)

PubMed: 32045997 ( click the link to review the publication )

Cancers (Basel), 2020, 12(2)

PubMed: 32093123 ( click the link to review the publication )

Cell Death Dis, 2020, 11(9):768

PubMed: 32943616 ( click the link to review the publication )

Cell Death Dis, 2020, 11(2):143

PubMed: 32081857 ( click the link to review the publication )

Br J Cancer, 2020, 10.1038/s41416-020-0952-1

PubMed: 32572172 ( click the link to review the publication )

Signal Transduct Target Ther, 2020, 5(1):214

PubMed: 33033232 ( click the link to review the publication )

Cancer Discov, 2020, 15 pii: CD-20-0116

PubMed: 32414908 ( click the link to review the publication )

Front Immunol, 2020, 10:3135

PubMed: 32082304 ( click the link to review the publication )

Mol Cancer Ther, 2020, 5 pii: molcanther

PubMed: 32371577 ( click the link to review the publication )

Mol Cell Proteomics, 2020, 31 pii: mcp

PubMed: 32234966 ( click the link to review the publication )

Neurobiol Dis, 2020, 9;104961

PubMed: 32531343 ( click the link to review the publication )

J Cancer, 2020, 6;11(13):3762-3770

PubMed: 32328181 ( click the link to review the publication )
Transl Lung Cancer Res, 2020, 9(5):1904-1914

PubMed: 33209611 ( click the link to review the publication )

Cancer Sci, 2020, 111(5):1652-1662

PubMed: 32133706 ( click the link to review the publication )

Cancer Sci, 2020, 111(10):3813-3823

PubMed: 32735723 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(12):4251-4265

PubMed: 33414998 ( click the link to review the publication )

Oncogenesis, 2020, 9(10):87

PubMed: 33012785 ( click the link to review the publication )

Biomolecules, 2020, 10(1)

PubMed: 31947839 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-19-0669

PubMed: 32238439 ( click the link to review the publication )

Mol Cancer Res, 2020, 25

PubMed: 32098826 ( click the link to review the publication )

Front Oncol, 2020, 9:1503

PubMed: 31993373 ( click the link to review the publication )

Front Oncol, 2020, 12;10:696

PubMed: 32528877 ( click the link to review the publication )

Front Oncol, 2020, 10:554704

PubMed: 33330026 ( click the link to review the publication )

Cell Microbiol, 2020, e13240

PubMed: 32584493 ( click the link to review the publication )

J Cell Mol Med, 2020, 24(10):5578-5592

PubMed: 32248643 ( click the link to review the publication )

J Cell Mol Med, 2020, 24(10):5811-5816

PubMed: 32281297 ( click the link to review the publication )

Int J Mol Sci, 2020,

PubMed: 32823915 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(20)E7770

PubMed: 33092268 ( click the link to review the publication )

Sci Rep, 2020, 10(1):17768

PubMed: 33082482 ( click the link to review the publication )

Sci Rep, 2020, 17;10(1):2735

PubMed: 32066763 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Biomed Pharmacother, 2020, 16;127:110225

PubMed: 32428834 ( click the link to review the publication )

Invest New Drugs, 2020, 38(4):1003-1011

PubMed: 31612426 ( click the link to review the publication )

Am J Transl Res, 2020, 12(11):7377-7385

PubMed: 33312374 ( click the link to review the publication )

Infect Immun, 2020, 88(4)e00819-19

PubMed: 31964750 ( click the link to review the publication )

Oncol Rep, 2020, 45(2):459-468

PubMed: 33416163 ( click the link to review the publication )
Eur J Pharmacol, 2020, 5;874:172961

PubMed: 32044322 ( click the link to review the publication )

J Pharm Biomed Anal, 2020, 195:113864

PubMed: 33387839 ( click the link to review the publication )

Thorac Cancer, 2020, 5

PubMed: 32368855 ( click the link to review the publication )

Thorac Cancer, 2020, 10.1111/1759-7714.13533

PubMed: 32558328 ( click the link to review the publication )

Thorac Cancer, 2020, 10.1111/1759-7714.13670

PubMed: 32956565 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

J Med Invest, 2020, 67(3.4):343-350

PubMed: 33148913 ( click the link to review the publication )

J Thorac Dis, 2020, 12(3):712-723

PubMed: 32274137 ( click the link to review the publication )

Int J Radiat Biol, 2020, 96(4):461-468

PubMed: 31859574 ( click the link to review the publication )

Cold Spring Harb Mol Case Stud, 2020,

PubMed: 32843430 ( click the link to review the publication )

Cell Death Dis, 2020, 11(8):670

PubMed: 32820157 ( click the link to review the publication )

Fundam Clin Pharmacol, 2020, 10.1111/fcp.12641

PubMed: 33336420 ( click the link to review the publication )

Front Oncol, 2020, 10:603883

PubMed: 33585221 ( click the link to review the publication )

BMC Cancer, 2020, 20(1):1189

PubMed: 33276757 ( click the link to review the publication )

Exp Mol Med, 2020, 10.1038/s12276-020-0474-1

PubMed: 32728068 ( click the link to review the publication )

Cells, 2020, 9(8):E1830

PubMed: 32756527 ( click the link to review the publication )

Cytometry A, 2020, 97(1):70-77

PubMed: 31411813 ( click the link to review the publication )

Redox Biol, 2020, 36:101652

PubMed: 32750669 ( click the link to review the publication )

Fundam Clin Pharmacol, 2020, 10.1111/fcp.12641

PubMed: 33336420 ( click the link to review the publication )

Cell Rep, 2020, 32(5):107994

PubMed: 32755586 ( click the link to review the publication )

Viruses, 2020, 12(11)E1294

PubMed: 33198108 ( click the link to review the publication )

Exp Cell Res, 2020, 390(2):111950

PubMed: 32188578 ( click the link to review the publication )

Cell Syst, 2020, S2405-4712(20)30247-7

PubMed: 32726596 ( click the link to review the publication )
Rapid Commun Mass Spectrom, 2020, 10.1002/rcm.8955

PubMed: 32990383 ( click the link to review the publication )

J Thorac Oncol, 2020, 15(5):752-765

PubMed: 31972351 ( click the link to review the publication )

Cancer Treat Res Commun, 2020, 25:100229

PubMed: 33152554 ( click the link to review the publication )

Exp Ther Med, 2020, 20(2):1415-1422

PubMed: 32742376 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(6):778-790

PubMed: 31160710 ( click the link to review the publication )

Mol Cell, 2019, 73(1):166-182

PubMed: 30609389 ( click the link to review the publication )

Hepatology, 2019, 10.1002/hep.30780

PubMed: 31127639 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2701

PubMed: 31221965 ( click the link to review the publication )

Nano Lett, 2019, 19(10):7526-7533

PubMed: 31487192 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2919

PubMed: 31266962 ( click the link to review the publication )

Autophagy, 2019, 10.1080/15548627.2019.1660545

PubMed: 31462148 ( click the link to review the publication )

EMBO J, 2019, 38(4)

PubMed: 30643021 ( click the link to review the publication )

Cancer Res, 2019, 79(4):819-829

PubMed: 30573522 ( click the link to review the publication )

J Am Soc Nephrol, 2019, 30(8):1454-1470

PubMed: 31253651 ( click the link to review the publication )

Matrix Biol, 2019, 10.1016/j.matbio.2019.07.006

PubMed: 31323325 ( click the link to review the publication )

Cell Rep, 2019, 26(1):65-78

PubMed: 30605687 ( click the link to review the publication )

Mol Cancer, 2019,

PubMed: 31747941 ( click the link to review the publication )

Elife, 2019,

PubMed: 31741433 ( click the link to review the publication )

Int J Cancer, 2019, 10.1002/ijc.32487

PubMed: 31162839 ( click the link to review the publication )

Int J Cancer, 2019, 145(5):1432-1444

PubMed: 30784054 ( click the link to review the publication )

Oncogene, 2019, 38(14):2464-2481

PubMed: 30532069 ( click the link to review the publication )

Oncogene, 2019, 38(11):1936-1950

PubMed: 30390071 ( click the link to review the publication )

Oncogene, 2019, 38(37):6399-6413

PubMed: 31324888 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):46

PubMed: 30709379 ( click the link to review the publication )
J Exp Clin Cancer Res, 2019, 38(1):96

PubMed: 30791926 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):481

PubMed: 31801598 ( click the link to review the publication )

Cancers (Basel), 2019, 11(1)

PubMed: 30609749 ( click the link to review the publication )

Cancers (Basel), 2019, 11(10)

PubMed: 31635301 ( click the link to review the publication )

Breast Cancer Res, 2019, 21(1):77

PubMed: 31262335 ( click the link to review the publication )

Cell Death Dis, 2019, 10(4):283

PubMed: 30911072 ( click the link to review the publication )

Signal Transduct Target Ther, 2019,

PubMed: 32651361 ( click the link to review the publication )

Signal Transduct Target Ther, 2019, 4:25

PubMed: 31637005 ( click the link to review the publication )

Cells, 2019, 8(12)

PubMed: 31795298 ( click the link to review the publication )

Cells, 2019, 8(12)E1495

PubMed: 31771093 ( click the link to review the publication )

Cell Physiol Biochem, 2019, 53(5):805-819

PubMed: 31670920 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163.MCT-19-0181

PubMed: 31501278 ( click the link to review the publication )

Cell Prolif, 2019, 52(6):e12680

PubMed: 31454111 ( click the link to review the publication )

Cell Prolif, 2019,

PubMed: 31094020 ( click the link to review the publication )

Neoplasia, 2019, 22(1):1-9

PubMed: 31751859 ( click the link to review the publication )

Biomolecules, 2019, 9(10)E638

PubMed: 31652643 ( click the link to review the publication )

Lung Cancer, 2019, 137:85-93

PubMed: 31563735 ( click the link to review the publication )

Cancer Biol Med, 2019, 16(3):606-617

PubMed: 31565489 ( click the link to review the publication )

Artif Cells Nanomed Biotechnol, 2019, 47(1):3231-3238

PubMed: 31373232 ( click the link to review the publication )

DNA Repair (Amst), 2019, 78:37-44

PubMed: 30954901 ( click the link to review the publication )

Front Oncol, 2019, 9:1167

PubMed: 31750252 ( click the link to review the publication )

Cancer Sci, 2019, 110(11):3584-3594

PubMed: 31446643 ( click the link to review the publication )

Biochem Pharmacol, 2019, 169:113640

PubMed: 31536726 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(19)

PubMed: 31546690 ( click the link to review the publication )
Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

Sci Rep, 2019,

PubMed: 31882684 ( click the link to review the publication )

J Biol Chem, 2019, 294(12):4488-4497

PubMed: 30679314 ( click the link to review the publication )

Mol Pharmacol, 2019, 95(5):528-536

PubMed: 30858165 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:117

PubMed: 31073278 ( click the link to review the publication )

Mol Carcinog, 2019, 10.1002/mc.23139

PubMed: 31777985 ( click the link to review the publication )

Mol Carcinog, 2019,

PubMed: 30811684 ( click the link to review the publication )

Front Pharmacol, 2019, 10:1116

PubMed: 31649529 ( click the link to review the publication )

Respir Res, 2019, 20(1-:270

PubMed: 31791326 ( click the link to review the publication )

Respir Res, 2019, 20(1):164

PubMed: 31331328 ( click the link to review the publication )

Biomed Pharmacother, 2019, 118:109169

PubMed: 31310954 ( click the link to review the publication )

J Proteomics, 2019, 195:114-124

PubMed: 30660770 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(10)

PubMed: 31121829 ( click the link to review the publication )

Int J Oncol, 2019, 54(2):527-536

PubMed: 30535494 ( click the link to review the publication )

Mediators Inflamm, 2019,

PubMed: 32082070 ( click the link to review the publication )

Life Sci, 2019, 224:23-32

PubMed: 30902544 ( click the link to review the publication )

J Drug Target, 2019, 27(4):451-459

PubMed: 30381967 ( click the link to review the publication )

Int J Biochem Cell Biol, 2019, 106:96-106

PubMed: 30471423 ( click the link to review the publication )

Molecules, 2019, 24(3)

PubMed: 30754629 ( click the link to review the publication )

Transl Oncol, 2019, 12(11):1516-1524

PubMed: 31450127 ( click the link to review the publication )

Eur J Pharmacol, 2019, 855:10-19

PubMed: 31028739 ( click the link to review the publication )

Eur J Pharmacol, 2019, 850:97-108

PubMed: 30753867 ( click the link to review the publication )

Eur J Pharmacol, 2019, 856:172409

PubMed: 31132355 ( click the link to review the publication )

Biosci Rep, 2019, 39(8)

PubMed: 31316001 ( click the link to review the publication )
PLoS ONE, 2019,

PubMed: 31891587 ( click the link to review the publication )

Onco Targets Ther, 2019, 12:6033-6043

PubMed: 31440060 ( click the link to review the publication )

Biomed Res Int, 2019, 2019:3129748

PubMed: 31346515 ( click the link to review the publication )

J Cancer Prev, 2019, 24(4):217-223

PubMed: 31950021 ( click the link to review the publication )

Mol Med Rep, 2019,

PubMed: 31638204 ( click the link to review the publication )

Oncol Lett, 2019, 18(5):5621-5627

PubMed: 31620204 ( click the link to review the publication )

Oncol Lett, 2019, 18(1):368-374

PubMed: 31289508 ( click the link to review the publication )

Anticancer Res, 2019, 39(7):3785-3793

PubMed: 31262905 ( click the link to review the publication )

Clin Respir J, 2019, 13(1):23-33

PubMed: 30480362 ( click the link to review the publication )

Exp Ther Med, 2019, 18(5):3793-3800

PubMed: 31611933 ( click the link to review the publication )

Exp Ther Med, 2019, 17(1):953-959

PubMed: 30651886 ( click the link to review the publication )

Cancer Immunol Res, 2019,

PubMed: 30975694 ( click the link to review the publication )

Zhongguo Fei Ai Za Zhi, 2019, 22(5):255-263

PubMed: 31109434 ( click the link to review the publication )

J Thorac Oncol, 2019, 14(9):1556-1566

PubMed: 31108249 ( click the link to review the publication )

Oncotarget, 2019, 10(11):1171-1192

PubMed: 30838090 ( click the link to review the publication )

Nat Microbiol, 2019, 4(2):216-225

PubMed: 30420785 ( click the link to review the publication )

JCI Insight, 2019, 4(21)

PubMed: 31600169 ( click the link to review the publication )

Oncotarget, 2019, 10(26):2546-2560

PubMed: 31069016 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(8):578-588

PubMed: 31015631 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(4):239-253

PubMed: 30936439 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4728

PubMed: 30413706 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2434

PubMed: 29934552 ( click the link to review the publication )

EMBO Mol Med, 2018, 10(3)

PubMed: 29449326 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(13):3097-3107

PubMed: 29506987 ( click the link to review the publication )
Clin Cancer Res, 2018, 24(16):3928-3940

PubMed: 29685880 ( click the link to review the publication )

EMBO Rep, 2018,

PubMed: 29335246 ( click the link to review the publication )

Theranostics, 2018, 8(5):1256-1269

PubMed: 29507618 ( click the link to review the publication )

J Control Release, 2018, 275:117-128

PubMed: 29474960 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):109

PubMed: 30157900 ( click the link to review the publication )

Oncogene, 2018, 37(12):1576-1593

PubMed: 29326440 ( click the link to review the publication )

Oncogene, 2018, 37(9):1251-1262

PubMed: 29242605 ( click the link to review the publication )

Cancer Lett, 2018, 424:84-96

PubMed: 29524558 ( click the link to review the publication )

Sci Signal, 2018, 11(549)

PubMed: 30254057 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 3;37(1):131

PubMed: 29970127 ( click the link to review the publication )

Cancers (Basel), 2018, 10(6)

PubMed: 29925812 ( click the link to review the publication )

FASEB J, 2018, 10.1096/fj.201800011R

PubMed: 29812969 ( click the link to review the publication )

Exp Mol Med, 2018, 50(1):e435

PubMed: 29371698 ( click the link to review the publication )

Exp Mol Med, 2018, 50(4):52

PubMed: 29700289 ( click the link to review the publication )

Cell Physiol Biochem, 2018,

PubMed: 29961070 ( click the link to review the publication )

Cell Physiol Biochem, 2018, 51(1):337-355

PubMed: 30453282 ( click the link to review the publication )

Endocr Relat Cancer, 2018, 25(4):471-480

PubMed: 29440231 ( click the link to review the publication )

Cell Commun Signal, 2018, 16(1):77

PubMed: 30409180 ( click the link to review the publication )

Mol Oncol, 2018,

PubMed: 29797762 ( click the link to review the publication )

Mol Oncol, 2018, 12(6):883-895

PubMed: 29633504 ( click the link to review the publication )

Mol Oncol, 2018, 12(2):224-238

PubMed: 29193645 ( click the link to review the publication )

Mol Cell Proteomics, 2018, 17(10):1892-1908

PubMed: 29970458 ( click the link to review the publication )

Eur J Med Chem, 2018, 144:330-348

PubMed: 29275232 ( click the link to review the publication )

Cancer Sci, 2018, 109(6):1775-1786

PubMed: 29624806 ( click the link to review the publication )
Oncogenesis, 2018, 7(9):67

PubMed: 30190455 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(3):543-553

PubMed: 29222171 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(10):1458-1469

PubMed: 29934325 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(11):1773-1784

PubMed: 29967110 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(7):1185-1195

PubMed: 29724813 ( click the link to review the publication )

J Immunol, 2018, 200(8):2809-2818

PubMed: 29531172 ( click the link to review the publication )

J Cell Sci, 2018,

PubMed: 29487179 ( click the link to review the publication )

Antiviral Res, 2018, 150:20-29

PubMed: 29224735 ( click the link to review the publication )

Biochem Pharmacol, 2018, 152:327-337

PubMed: 29660315 ( click the link to review the publication )

Sci Rep, 2018, 8(1):18043

PubMed: 30575780 ( click the link to review the publication )

J Biol Chem, 2018, 293(35):13401-13414

PubMed: 29997256 ( click the link to review the publication )

Respir Res, 2018, 19(1):96

PubMed: 29784046 ( click the link to review the publication )

Cancer Manag Res, 2018, 10:5785-5798

PubMed: 30510448 ( click the link to review the publication )

Cancer Manag Res, 2018, 10:6695-6703

PubMed: 30584364 ( click the link to review the publication )

Cancer Commun (Lond), 2018, 38(1):50

PubMed: 30053908 ( click the link to review the publication )

Phytomedicine, 2018, 39:33-41

PubMed: 29433681 ( click the link to review the publication )

Int J Oncol, 2018, 52(6):2143-2154

PubMed: 29620166 ( click the link to review the publication )

Invest New Drugs, 2018, 36(6):999-1005

PubMed: 29594878 ( click the link to review the publication )

Cancer Biol Ther, 2018, 19(10):921-933

PubMed: 29856687 ( click the link to review the publication )

Cell Cycle, 2018, 17(23):2577-2592

PubMed: 30488756 ( click the link to review the publication )

Transl Oncol, 2018, 11(6):1406-1418

PubMed: 30219696 ( click the link to review the publication )

Oncol Rep, 2018, 40(4):2171-2182

PubMed: 30106444 ( click the link to review the publication )

Oncol Rep, 2018, 40(4):1937-1946

PubMed: 30106446 ( click the link to review the publication )

Oncol Rep, 2018, 40(2):775-782

PubMed: 29901173 ( click the link to review the publication )
Oncol Rep, 2018, 40(2):1046-1054

PubMed: 29917169 ( click the link to review the publication )

Onco Targets Ther, 2018, 11:8455-8463

PubMed: 30555238 ( click the link to review the publication )

J Gen Virol, 2018,

PubMed: 29624161 ( click the link to review the publication )

J Ovarian Res, 2018, 11(1):12

PubMed: 29402301 ( click the link to review the publication )

Cell Biol Int, 2018, 42(10):1311-1320

PubMed: 29907991 ( click the link to review the publication )

Mol Med Rep, 2018, 18(4):3882-3890

PubMed: 30106133 ( click the link to review the publication )

Oncol Lett, 2018, 15(3):2829-2838

PubMed: 29467862 ( click the link to review the publication )

Cell Mol Biol (Noisy-le-grand), 2018, 64(4):6-10

PubMed: 29631678 ( click the link to review the publication )

Oncotarget, 2018, 9(51):29680-29697

PubMed: 30038713 ( click the link to review the publication )

Oncotarget, 2018, 9(26):18254-18268

PubMed: 29719603 ( click the link to review the publication )

Oncotarget, 2018,

PubMed: 29416603 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2018, 115(42):E9869-E9878

PubMed: 30275324 ( click the link to review the publication )

Nat Commun, 2017, 8;8:15617

PubMed: 28593995 ( click the link to review the publication )

Nat Commun, 2017, 8(1):410

PubMed: 28871105 ( click the link to review the publication )

Nat Commun, 2017, 1;8(1):1232

PubMed: 29089541 ( click the link to review the publication )

Autophagy, 2017, 13(7):1093-1112

PubMed: 28513279 ( click the link to review the publication )

Neuro-oncology, 2017,

PubMed: 28575494 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(15):E3129-E3138

PubMed: 28351972 ( click the link to review the publication )

Genes Dev, 2017, 31(2):184-196

PubMed: 28167502 ( click the link to review the publication )

Genes Dev, 2017, 31(17):1754-1769

PubMed: 28982759 ( click the link to review the publication )

Cancer Res, 2017, 77(13):3551-3563

PubMed: 28428274 ( click the link to review the publication )

Cell Rep, 2017, 21(11):3298-3309

PubMed: 29241554 ( click the link to review the publication )

Mol Cancer, 2017, 16(1):34

PubMed: 28158983 ( click the link to review the publication )

Elife, 2017, 6e26733

PubMed: 28737489 ( click the link to review the publication )
Int J Cancer, 2017, 141(9):1921-1931

PubMed: 28710768 ( click the link to review the publication )

ACS Photonics, 2017, 5(2):487-494

PubMed: 29805987 ( click the link to review the publication )

Oncogene, 2017, 36(8):1102-1111

PubMed: 27524413 ( click the link to review the publication )

Oncogene, 2017, 36(48):6691-6700

PubMed: 28745317 ( click the link to review the publication )

Oncogene, 2017, 36(6):731-745

PubMed: 27477696 ( click the link to review the publication )

J Med Chem, 2017, 60(17):7447-7458

PubMed: 28787156 ( click the link to review the publication )

Arch Toxicol, 2017, 91(8):2921-2938

PubMed: 28032146 ( click the link to review the publication )

ACS Infect Dis, 2017, 3(8):564-574

PubMed: 28537707 ( click the link to review the publication )

Transl Lung Cancer Res, 2017, 6(5):600-610

PubMed: 29114475 ( click the link to review the publication )

Cancer Sci, 2017, 108(7):1368-1377

PubMed: 28445002 ( click the link to review the publication )

Sci Rep, 2017,

PubMed: 28684780 ( click the link to review the publication )

Sci Rep, 2017,

PubMed: 28939861 ( click the link to review the publication )

Acta Pharmacol Sin, 2017, 38(11):1501-1511

PubMed: 29022575 ( click the link to review the publication )

BMC Cancer, 2017,

PubMed: 28806950 ( click the link to review the publication )

Oncol Rep, 2017, 38(4):2205-2210

PubMed: 28791365 ( click the link to review the publication )

Eur J Pharmacol, 2017, 821:21-28

PubMed: 29277715 ( click the link to review the publication )

Oncol Rep, 2017, 37(2):1212-1218

PubMed: 27959426 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 493(1):213-219

PubMed: 28899783 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 482(4):1334-1340

PubMed: 27939888 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 486(4):1027-1033

PubMed: 28366635 ( click the link to review the publication )

SLAS Discov, 2017, 22(7):915-922

PubMed: 28346107 ( click the link to review the publication )

Oncol Lett, 2017,

PubMed: 28927099 ( click the link to review the publication )

Oncol Lett, 2017, 14(4):4349-4354

PubMed: 28959367 ( click the link to review the publication )

Oncotarget, 2017, 8(40):69185-69197

PubMed: 28978189 ( click the link to review the publication )
Oncotarget, 2017, 8(3):4277-4288

PubMed: 28032592 ( click the link to review the publication )

Oncotarget, 2017, 8(14):22325-22343

PubMed: 28423611 ( click the link to review the publication )

Oncotarget, 2017, 8(54):92240-92253

PubMed: 29190911 ( click the link to review the publication )

Oncotarget, 2017, 8(14):22414-22432

PubMed: 26461472 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 28423644 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(2):233-246

PubMed: 27989769 ( click the link to review the publication )

Oncotarget, 2017, 8(70):115620-115631

PubMed: 29383186 ( click the link to review the publication )

Oncotarget, 2017, 8(29):47305-47316

PubMed: 28521301 ( click the link to review the publication )

Oncotarget, 2017, 8(35):58771-58780

PubMed: 28938595 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 28427242 ( click the link to review the publication )

Oncotarget, 2017, 9(2):1641-1655

PubMed: 29416720 ( click the link to review the publication )

Hepatology, 2016, 64(2):488-500

PubMed: 27015352 ( click the link to review the publication )

Genome Biol, 2016, 17:80

PubMed: 27139883 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

J Clin Invest, 2016, 126(9):3296-312

PubMed: 27482886 ( click the link to review the publication )

Nat Commun, 2016, 7:12231

PubMed: 27456471 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(21):5370-5382

PubMed: 27178741 ( click the link to review the publication )

EMBO Rep, 2016, 17(5):724-38

PubMed: 27013495 ( click the link to review the publication )

Oncogene, 2016,

PubMed: 26640141 ( click the link to review the publication )

J Pathol, 2016, 239(3):320-34

PubMed: 27102572 ( click the link to review the publication )

Acta Neuropathol Commun, 2016, 4(1):96

PubMed: 27586084 ( click the link to review the publication )

Mol Cancer Ther, 2016, 10.1158/1535-7163.MCT-15-0375

PubMed: 27196768 ( click the link to review the publication )

Mol Cancer Ther, 2016,

PubMed: 27678331 ( click the link to review the publication )

Oral Oncol, 2016, 59:12-19

PubMed: 27424178 ( click the link to review the publication )
Oral Oncol, 2016, 56:62-70

PubMed: 27086488 ( click the link to review the publication )

Biochim Biophys Acta, 2016, 10.1016/j.bbagen.2016.05.011

PubMed: 27180173 ( click the link to review the publication )

Biochim Biophys Acta, 2016, 1859(11):1449-1458

PubMed: 27412911 ( click the link to review the publication )

Sci Rep, 2016, 6:32258

PubMed: 27558531 ( click the link to review the publication )

Clin Lung Cancer, 2016, 17(4):263-270

PubMed: 26707383 ( click the link to review the publication )

J Proteome Res, 2016, 15(12):4490-4504

PubMed: 27794612 ( click the link to review the publication )

Int J Oncol, 2016, 49(4):1427-36

PubMed: 27498706 ( click the link to review the publication )

Int J Oncol, 2016, 48(3):937-44

PubMed: 26783187 ( click the link to review the publication )

Exp Cell Res, 2016, 344(2):194-200

PubMed: 27180268 ( click the link to review the publication )

Eur J Pharmacol, 2016, 789:458-467

PubMed: 27514773 ( click the link to review the publication )

Oncol Rep, 2016, 36(2):729-36

PubMed: 27373987 ( click the link to review the publication )

Neurosurg Focus, 2016, 41(6):E14

PubMed: 27903123 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155230

PubMed: 27153109 ( click the link to review the publication )

PLoS One, 2016, 11(9):e0163149

PubMed: 27643613 ( click the link to review the publication )

Anal Biochem, 2016,

PubMed: 27059751 ( click the link to review the publication )

Oncotarget, 2016, 7(23):34395-419

PubMed: 27284014 ( click the link to review the publication )

Oncotarget, 2016, 7(51):84951-84964

PubMed: 27825114 ( click the link to review the publication )

Oncotarget, 2016, 7(37):59809-59819

PubMed: 27494858 ( click the link to review the publication )

Oncotarget, 2016, 7(4):3847-56

PubMed: 26716903 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27590506 ( click the link to review the publication )

Oncotarget, 2016, 7(31):50258-50276

PubMed: 27384680 ( click the link to review the publication )

Oncotarget, 2016, 7(19):27959-74

PubMed: 27058897 ( click the link to review the publication )

Tumour Biol, 2016,

PubMed: 26286833 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27556697 ( click the link to review the publication )
Oncotarget, 2016, 7(18-:25983-6002

PubMed: 27036020 ( click the link to review the publication )

Oncotarget, 2016, 7(32):52392-52403

PubMed: 27447558 ( click the link to review the publication )

Cell Res, 2015, 10.1038/cr.2015.16

PubMed: 25656847 ( click the link to review the publication )

Nat Commun, 2015, 6:6377

PubMed: 25758528 ( click the link to review the publication )

Nat Commun, 2015, 6:6240

PubMed: 25670642 ( click the link to review the publication )

J Thorac Oncol, 2015, 10.1097/JTO.0000000000000500

PubMed: 25658629 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-14-2789

PubMed: 25948633 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-15-0560

PubMed: 25964297 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2015, 112(6):1839-44

PubMed: 25605917 ( click the link to review the publication )

EMBO Rep, 2015,

PubMed: 26341626 ( click the link to review the publication )

Cell Rep, 2015, 10.1016/j.celrep.2015.04.049

PubMed: 26027934 ( click the link to review the publication )

Int J Cancer, 2015, 137(12):2947-58

PubMed: 26089022 ( click the link to review the publication )

Oncogene, 2015,

PubMed: 25746002 ( click the link to review the publication )

Cancer Lett, 2015, 369(1):103-11

PubMed: 26297988 ( click the link to review the publication )

Cell Death Dis, 2015,

PubMed: 26469972 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(10-:2238-48

PubMed: 26208525 ( click the link to review the publication )

Mol Oncol, 2015, 9(2):527-43

PubMed: 25454348 ( click the link to review the publication )

Mol Cell Proteomics, 2015, 10.1074/mcp.M115.049783 mcp.M115.049783.

PubMed: 25953087 ( click the link to review the publication )

Lung Cancer, 2015, 88(1):16-23

PubMed: 25704955 ( click the link to review the publication )

Sci Rep, 2015,

PubMed: 26268703 ( click the link to review the publication )

Sci Rep, 2015,

PubMed: 25705018 ( click the link to review the publication )

Sci Rep, 2015,

PubMed: 26639561 ( click the link to review the publication )

J Biol Chem, 2015, 290(41):24784-92

PubMed: 26304118 ( click the link to review the publication )

Biochem J, 2015, 465(2):271-9

PubMed: 25351958 ( click the link to review the publication )
J Chromatogr A, 2015, 10.1016/j.chroma.2015.04.055

PubMed: ( click the link to review the publication )

J Chromatogr A, 2015, 1400:117-23

PubMed: 25981288 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2015, 10.1016/j.taap.2015.05.001

PubMed: 25981168 ( click the link to review the publication )

Breast Cancer Res Treat, 2015, 154(2):225-37

PubMed: 26487496 ( click the link to review the publication )

Int J Oncol, 2015, 46(3):1214-24

PubMed: 25530180 ( click the link to review the publication )

Oncol Rep, 2015, 33(4):1860-6

PubMed: 25634113 ( click the link to review the publication )

Oncol Rep, 2015, 34(3):1613-9

PubMed: 26166014 ( click the link to review the publication )

Oncol Rep, 2015, 34(4):1875-82

PubMed: 26238612 ( click the link to review the publication )

PLoS ONE, 2015,

PubMed: 25969993 ( click the link to review the publication )

PLoS One, 2015, 10(12):e0144368

PubMed: 26656173 ( click the link to review the publication )

Pathol Oncol Res, 2015, 10.1007/s12253-015-9916-9

PubMed: 25749811 ( click the link to review the publication )

Mol Med Rep, 2015,

PubMed: 25483995 ( click the link to review the publication )

Oncol Lett, 2015,

PubMed: 26622654 ( click the link to review the publication )

Anticancer Res, 2015, 35(5):2795-803

PubMed: 25964559 ( click the link to review the publication )

Oncotarget, 2015, 6(27):23857-73

PubMed: 26160843 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 25909220 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2015, 10.1016/j.ijrobp.2015.01.026

PubMed: 25823448 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5118-33

PubMed: 25742786 ( click the link to review the publication )

Oncoscience, 2015, 2(4):419-427

PubMed: 26097875 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26378037 ( click the link to review the publication )

Oncotarget, 2015, 6(12):10146-60

PubMed: 25760142 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 25965827 ( click the link to review the publication )

Sci Transl Med, 2014, 6(219):219ra9

PubMed: 24431113 ( click the link to review the publication )

Mol Cell, 2014, 55(6):904-15

PubMed: 25219500 ( click the link to review the publication )
Cancer Res, 2014, 74(1):253-62

PubMed: 24165158 ( click the link to review the publication )

Elife, 2014, 3:e02523

PubMed: 24844246 ( click the link to review the publication )

Int J Cancer, 2014, 134(11):2560-71

PubMed: 24374738 ( click the link to review the publication )

Oncogene, 2014, 33(19):2495-503

PubMed: 23728339 ( click the link to review the publication )

Oncogene, 2014, 33(35):4385-95

PubMed: 24096476 ( click the link to review the publication )

MBio, 2014, 5(4):e01340-14

PubMed: 25096879 ( click the link to review the publication )

Cancer Lett, 2014, 342(1):82-91

PubMed: 24001610 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1445

PubMed: 25299770 ( click the link to review the publication )

Mol Oncol, 2014, 10.1016/j.molonc.2014.05.005

PubMed: 24908424 ( click the link to review the publication )

Mol Oncol, 2014, 9(1):260-9

PubMed: 25226813 ( click the link to review the publication )

Cell Oncol , 2014, 37(5):377-86

PubMed: 25228008 ( click the link to review the publication )

Lung Cancer, 2014, 85(2):141-6

PubMed: 24957682 ( click the link to review the publication )

J Cell Sci, 2014, 127(Pt 16):3555-67

PubMed: 24951116 ( click the link to review the publication )

Antimicrob Agents Chemother, 2014, 10.1128/AAC.02393-14

PubMed: 24663025 ( click the link to review the publication )

Int J Biol Sci, 2014,

PubMed: 25013379 ( click the link to review the publication )

Colloids and Surfaces B: Biointerfaces, 2014, 123:61-7

PubMed: 25216919 ( click the link to review the publication )

Drug Metab Dispos, 2014, 42(3):318-22

PubMed: 24335466 ( click the link to review the publication )

Drug Metab Dispos, 2014, 42(11):1851-7

PubMed: 25165131 ( click the link to review the publication )

Int J Oncol, 2014, 45(1):393-400

PubMed: 24819550 ( click the link to review the publication )

Prostate, 2014, 74(5):528-36

PubMed: 24435707 ( click the link to review the publication )

Cell Cycle, 2014,

PubMed: 25426675 ( click the link to review the publication )

Cell Cycle, 2014, 13(24):3808-17

PubMed: ( click the link to review the publication )

Am J Physiol Renal Physiol, 2014, 307(4):F435-44

PubMed: 24990892 ( click the link to review the publication )

Oncol Rep, 2014, 32(5):2230-6

PubMed: 25175149 ( click the link to review the publication )
Cancer Chemoth Pharm, 2014, 74(3):511-20

PubMed: 25038613 ( click the link to review the publication )

PLoS One, 2014, 9(12):e115144

PubMed: 25502225 ( click the link to review the publication )

PLoS One, 2014, 9(4):e93651

PubMed: 24695557 ( click the link to review the publication )

PLoS One, 2014, 9(4):e95243

PubMed: 24743578 ( click the link to review the publication )

PLoS One, 2014, 9(12):e114000

PubMed: 25486409 ( click the link to review the publication )

PLoS One, 2014, 9(5):e97719

PubMed: 24874286 ( click the link to review the publication )

Biomed Res Int, 2014,

PubMed: 24895573 ( click the link to review the publication )

Horm Cancer, 2014, 289(24):17195-202

PubMed: 24778185 ( click the link to review the publication )

Exp Mol Pathol, 2014, 97(1):154-165

PubMed: 24984270 ( click the link to review the publication )

Langenbecks Arch Surg, 2014, 10.1007/s00423-014-1235-1

PubMed: 25070024 ( click the link to review the publication )

J BUON, 2014, 19(2):466-73

PubMed: 24965408 ( click the link to review the publication )

Korean J Parasitol, 2014, 52(4):439-41

PubMed: 25246725 ( click the link to review the publication )

Oncotarget, 2014,

PubMed: 25277177 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2014, 88(4):947-54

PubMed: 24606853 ( click the link to review the publication )

University of Alberta, 2014, Yahya Muhammad Fiteih

PubMed: ( click the link to review the publication )

Oncotarget, 2014, 5(13):4765-78

PubMed: 24946858 ( click the link to review the publication )

Guangxi Medical University, 2014, Suning Huang

PubMed: ( click the link to review the publication )

JBUON , 2014, 19(2): 466-473

PubMed: ( click the link to review the publication )

Oncotarget, 2014, 5(15):5908-19

PubMed: 25115383 ( click the link to review the publication )

Ann Oncol, 2013, 24(2):362-9

PubMed: 22967992 ( click the link to review the publication )

Neuro Oncol, 2013, 15(11):1469-78

PubMed: 24101737 ( click the link to review the publication )

J Cell Biol, 2013, 201(2):279-92

PubMed: 23589494 ( click the link to review the publication )

Sci Signal, 2013, 6(279):ra45

PubMed: 23757022 ( click the link to review the publication )

J Clin Endocrinol Metab, 2013, 98(6):2502-12

PubMed: 23559083 ( click the link to review the publication )
Mol Cancer Ther, 2013, 13(2):444-53

PubMed: 24258346 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(11):2541-58

PubMed: 24026012 ( click the link to review the publication )

Mol Oncol, 2013, 7(1):121-9

PubMed: 23127547 ( click the link to review the publication )

Carcinogenesis, 2013, 34(9):1994-9

PubMed: 23677069 ( click the link to review the publication )

Cell Prolif, 2013, 46(4):447-56

PubMed: 23829318 ( click the link to review the publication )

Radiother Oncol, 2013, 108(3):473-8

PubMed: 23891090 ( click the link to review the publication )

J Biol Chem, 2013, 288(48):34930-42

PubMed: 24142702 ( click the link to review the publication )

Drug Metab Dispos, 2013, 10.1124/dmd.113.054189

PubMed: 24335466 ( click the link to review the publication )

Prostate, 2013, 73(13):1453-61

PubMed: 23765757 ( click the link to review the publication )

PLoS One, 2013, 8(12):e82236

PubMed: 24349229 ( click the link to review the publication )

PLoS One, 2013, 8(12):e81393

PubMed: 24339922 ( click the link to review the publication )

PLoS One, 2013, 8(5):e62852

PubMed: 23696788 ( click the link to review the publication )

PLoS One, 2013, 8(12):e82625

PubMed: 24349321 ( click the link to review the publication )

Lipids Health Dis, 2013, 12:101

PubMed: 23849180 ( click the link to review the publication )

Exp Mol Pathol, 2013, 94(2):386-97

PubMed: 23399805 ( click the link to review the publication )

Evid Based Complement Alternat Med, 2013, 2013:243859

PubMed: 23533466 ( click the link to review the publication )

J Genet Syndr Gene Ther, 2013, 4

PubMed: 25520884 ( click the link to review the publication )

Herpesviridae, 2013, 4(1):1

PubMed: 23342981 ( click the link to review the publication )

Oncotarget, 2013, 4(10):1698-1711

PubMed: 24091605 ( click the link to review the publication )

Tuberc Respir Dis, 2013, 75(3):95-103

PubMed: 24101933 ( click the link to review the publication )

Cell Death Differ, 2012, 19(12):1908-16

PubMed: 22722337 ( click the link to review the publication )

Int J Cancer, 2012, 131(12):2961-9

PubMed: 22514082 ( click the link to review the publication )

Int J Cancer, 2012, 131(2):334-43

PubMed: 21858806 ( click the link to review the publication )

Oncogene, 2012, 32(34):4034-42

PubMed: 22964644 ( click the link to review the publication )
Cancer Lett, 2012, 321(2):187-94

PubMed: 22343320 ( click the link to review the publication )

J Cell Sci, 2012, 125(Pt 2):435-48

PubMed: 22357970 ( click the link to review the publication )

Cancer Sci, 2012, 103(1):7-16

PubMed: 21951556 ( click the link to review the publication )

Biochem Pharmacol, 2012, 84(4):425-31

PubMed: 22634404 ( click the link to review the publication )

Int J Mol Sci, 2012, 13(9):12000-16

PubMed: 23109896 ( click the link to review the publication )

Int J Oncol, 2012, 41(3):869-75

PubMed: 22752005 ( click the link to review the publication )

Cancer Res Treat, 2012, 44(3):202-9

PubMed: 23091447 ( click the link to review the publication )

PLoS One, 2012, 7(9):e42441

PubMed: 22957020 ( click the link to review the publication )

PLoS One, 2012, 7(12):e51549

PubMed: 23272116 ( click the link to review the publication )

Oncotarget, 2012, 2(12):1134-44

PubMed: 22193779 ( click the link to review the publication )

Mol Syst Biol, 2011, 7:486

PubMed: 21525872 ( click the link to review the publication )

Oncogene, 2011, 30(6):737-50

PubMed: 20890302 ( click the link to review the publication )

Antivir Res, 2011, 89(1):64-70

PubMed: 21094187 ( click the link to review the publication )

J Immunother, 2011, 34(4):372-81

PubMed: 21499124 ( click the link to review the publication )

Mol Biosyst, 2011, 7(12):3223-33

PubMed: 21956701 ( click the link to review the publication )

Exp Mol Pathol, 2011, 91(1):400-10

PubMed: 21565184 ( click the link to review the publication )

Vet Comp Oncol, 2011, 11(2):124-39

PubMed: 22235915 ( click the link to review the publication )

Int J Proteomics, 2011, 2011:215496

PubMed: 22091388 ( click the link to review the publication )

Carcinogenesis, 2010, 31(11):1948-55

PubMed: 20837598 ( click the link to review the publication )

Purity & Quality Control

Choose Selective EGFR Inhibitors

Biological Activity

Description

Features

A potent EGFR tyrosine kinase inhibitor.

Targets

Tyr1173 (NR6W cells) ^[1]	Tyr1173 (NR6wtEGFR cells) ^[1]	Tyr992 (NR6wtEGFR cells) ^[1]	Tyr992 (NR6W cells) ^[1]
26 nM	37 nM	37 nM	57 nM

In vitro

Gefitinib effectively inhibits all tyrosine phosphorylation sites on EGFR in both the high and low-EGFR-expressing cell lines including NR6, NR6M and NR6W cell lines. The phosphorylation sites Tyr1173 and Tyr992 are less sensitive requiring higher concentrations of Gefitinib for inhibition. Gefitinib effectively blocks the phosphorylation of PLC-γ, with IC50 of 27nM, in NR6W cells. The NR6wtEGFR and NR6M cell lines has low levels of PLC-γ phosphorylation but the level in the NR6M cell line is more resistant to inhibition by Gefitinib with IC50 of 43 nM and 369 nM, respectively. Gefitinib inhibits Akt phosphorylations, with IC50 of 220 and 263nM, in the low-EGFR- and -EGFRvIII-expressing cell lines, respectively. Gefitinib in the dose range from 0.1 to 0.5μM significantly facilitates, rather than abrogates, colony formation of NR6M cells. However, at a concentration of 2 μM Gefitinib completely blocks NR6M colony formation. Gefitinib rapidly and in a dose-dependent manner inhibits EGFR and ERK phosphorylation up to 72 hours after EGF stimulation in both the high- and low-EGFR-expressing cell lines. ^[1] Gefitinib is the monolayer growth of these EGF-driven untransformed MCF10A cells with an IC50 of 20 nM. ^[2] The combination of Gefitinib (0.2 μM and 0.5 μM) with irradiation lead to a significant growth inhibition in LoVo cells, compared with radiation alone.. ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
NCI-H1975	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXPhVWRrUUN3ME2yNU41PjFizszN	NImxTnY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
HT	NUXGbYU1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkjBTWM2OD1{MT60N\|MyKM7:TR?=	M4T2c\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
HUTU-80	NYi3N4ZqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV\JR\|UxRTJzLkSzN\|Yh\|ryP	MmTrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
PA-1	M{XPOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmnwTWM2OD1{MT6yO\|g4KM7:TR?=	MnrPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
HOP-62	MlP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2XZ[GlEPTB;MkGuNlc5PCEQvF2=	NInHdZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
GI-1	NXyxVIJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MniyTWM2OD1{MT6xO{DPxE1?	NELjR4o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
MC116	NH\BVndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIi3fmhKSzVyPUKxMlA4OjNizszN	NFf1WZM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
A375	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH\tZpdKSzVyPUKxMlA2PjdizszN	MlzZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
IST-SL1	NYryfVRIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXHJR\|UxRTJyLke4O\|kh\|ryP	MmniQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
TE-5	M{nwVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4HtemlEPTB;MkCuO\|Q5OiEQvF2=	M4XNUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
SiHa	M2rmNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1LJZ2lEPTB;MkCuN\|cyOiEQvF2=	NH3UNo09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
LB2518-MEL	NFLTUYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2jremlEPTB;MkCuN\|c{QSEQvF2=	NUjVVXpHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
BB49-HNC	NWfh[IUyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mme3TWM2OD1zOT65NkDPxE1?	M3LlflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
HGC-27	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUDJR\|UxRTJyLkGzPVQh\|ryP	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
Becker	NGfCSI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVP4ZW1kUUN3ME2xPU45PTR5IN88US=>	MmH4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
TYK-nu	NUToeIR{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkHlTWM2OD1zOT64N\|c5KM7:TR?=	MojkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
NCI-H650	NVft[JRIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH[3V3RKSzVyPUG5Mlc2ODhizszN	NXOyfFFHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
WM-115	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1L1WWlEPTB;MUmuOlc4PCEQvF2=	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
HuH-7	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1\oZmlEPTB;MUmuO\|QzOSEQvF2=	MmTjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
NCI-N87	MlH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn\YTWM2OD1zOT61PVkzKM7:TR?=	M4nKSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
NCI-H1048	M2n1Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVvMVGhvUUN3ME2xPU4zOzJ4IN88US=>	M4PhbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
NCI-H446	NECzcZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXHJR\|UxRTF7LkO1PFkh\|ryP	NEPHXlk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
NCI-H1437	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnfDTWM2OD1zOT6wOFY4KM7:TR?=	M3\2WVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
D-263MG	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4TRXWlEPTB;MUmuNFE4OiEQvF2=	M1HsVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
MFH-ino	NELJbINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml7nTWM2OD1zOD65OlY6KM7:TR?=	NWHDSoZpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
U-266	NVXROVE3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWnJR\|UxRTF6Lki2OFkh\|ryP	NH\sTnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
OVCAR-8	M3jBUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mme4TWM2OD1zOD65Nlc3KM7:TR?=	NULGPWdwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
KNS-42	Mom1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV7JR\|UxRTF6LkiwNVUh\|ryP	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
U251	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1zkZ2lEPTB;MUiuO\|M1PyEQvF2=	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
MFE-280	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWHJR\|UxRTF6LkeyPVMh\|ryP	NVvmXXVXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
NCI-H1563	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnTkTWM2OD1zOD63NVI1KM7:TR?=	NETF[Xo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
MDA-MB-361	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWnJR\|UxRTF6LkW1PFgh\|ryP	M3XIXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
HLE	NW[5OYtIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVHJR\|UxRTF6LkOxOFgh\|ryP	NVXBPYU1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
SW982	NGW1emVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEK2U41KSzVyPUG4MlQxPzVizszN	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
KM-H2	NIDqcmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVr5cnNHUUN3ME2xO{46PDFzIN88US=>	M3\DelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
D-502MG	NVXiSJR1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mmq1TWM2OD1zNz65PFA5KM7:TR?=	NILrSHU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
ES8	M1q4TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MULJR\|UxRTF5Lki1PVMh\|ryP	NX\vdlBERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
SF268	MkXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUjHO4RwUUN3ME2xO{43QTZ7IN88US=>	MlLlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
Calu-6	NWnkW25xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUXncmVVUUN3ME2xO{43Pzh{IN88US=>	MlKzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
SW1783	NVTDNmxET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlLVTWM2OD1zNz62OFE2KM7:TR?=	M4[zWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
NCI-H747	NUL1UnkxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnPLTWM2OD1zNz61Nlk4KM7:TR?=	NFvTWGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
NCI-H1573	MoX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVPrfVFQUUN3ME2xO{4zQDJ4IN88US=>	MoTrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
NCI-H1581	NFvG[IdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlS3TWM2OD1zNz60OFEyKM7:TR?=	M324U\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
RKO	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHXVXXpKSzVyPUG3MlA4PDhizszN	NVnFRmZWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
MZ2-MEL	NGXOXWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWLJR\|UxRTF5LkGzN{DPxE1?	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
GI-ME-N	NX3pVXBqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmfiTWM2OD1zNj65NFMzKM7:TR?=	NFu2eVM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
LB373-MEL-D	Mk\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmLsTWM2OD1zNj63NlMzKM7:TR?=	Ml3JQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
MEL-HO	M3PlVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1rTZWlEPTB;MU[uPFg2PCEQvF2=	NIn2bVY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
BEN	NEHvVVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYDJR\|UxRTF4LkWxOVUh\|ryP	NYHUXG1bRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
M059J	NUPneXB1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWPKN4JbUUN3ME2xOk4zQDRizszN	NFTqTIE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
D-283MED	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnTSTWM2OD1zNj60NlA6KM7:TR?=	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
GP5d	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1XQfmlEPTB;MU[uNlE5PyEQvF2=	NFfTPVA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
BHT-101	M3HMRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGrZO4pKSzVyPUG2MlI1OzlizszN	NH\TW2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
HT55	NED4blBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUT2dpF3UUN3ME2xOU46PDd6IN88US=>	NXLUe4Z5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
no-11	M1rBUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3LXWmlEPTB;MUWuPVY3OyEQvF2=	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
MPP-89	NXyzfJp2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYTJR\|UxRTF3Lkm0NVch\|ryP	NF7FcFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
HuCCT1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXrrT41iUUN3ME2xOU45PzRizszN	NE\LPWQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
NCI-H23	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXfJR\|UxRTF3Lki0N\|gh\|ryP	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
UMC-11	MkXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFXJOoxKSzVyPUG1Mlc2OjNizszN	MkHMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
MCF7	NXjkWY93T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF7XdodKSzVyPUG1MlgyPDVizszN	NI\t[Y89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
COLO-320-HSR	MlHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn7TTWM2OD1zNT61N\|A4KM7:TR?=	Ml\oQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
CW-2	MmOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mo\kTWM2OD1zNT6xOFIyKM7:TR?=	M4L0fFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
MOLT-4	NYDIXndGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUn5ZVhSUUN3ME2xOU4xPDl5IN88US=>	M1zVb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
NCI-H1755	M{XpR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MonJTWM2OD1zND65PVU{KM7:TR?=	NFKwc\|c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
MIA-PaCa-2	NH\kT3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVXJR\|UxRTF2Lkm2PUDPxE1?	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
TGBC1TKB	NV:0dWZDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2XhZmlEPTB;MUSuOlYyPSEQvF2=	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
NCI-H630	MkfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoHLTWM2OD1zND65OFY4KM7:TR?=	M4DVNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
LAN-6	MlrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NULWOGlJUUN3ME2xOE4zPTNizszN	NUDkO\|NiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
A549	NVvjO4Z1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NInPV5dKSzVyPUG0MlQ4OTJizszN	NEXIZmo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
RD	M{XHV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVTJR\|UxRTF2LkS4NVMh\|ryP	MkThQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
KALS-1	NVHoZXVoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXHzNoJSUUN3ME2xN{45PTJ3IN88US=>	NF3zR3g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
LOXIMVI	NV7zO\|I3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{DW[WlEPTB;MUOuOlE2OSEQvF2=	Mn3JQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
SK-PN-DW	M1e5OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MojiTWM2OD1zMz64OFI4KM7:TR?=	MknCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
SN12C	M2nJOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVXJR\|UxRTF\|LkO4NFgh\|ryP	MnPWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
NCI-H1993	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2\QS2lEPTB;MUOuOFI5PSEQvF2=	NX7aSnBxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
G-361	NVz5dFlKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{HiUGlEPTB;MUKuPVEzQSEQvF2=	NGHNW5E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
RH-18	MnvHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUXsbHd7UUN3ME2xN{4zQTZ{IN88US=>	MoHYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
GT3TKB	M3rGbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXiyTIR{UUN3ME2xNk43OzJ5IN88US=>	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
DMS-273	MnToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{XaZ2lEPTB;MUKuPFY{OyEQvF2=	NHK0b5k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
C3A	M33vO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{PHeWlEPTB;MUKuOVc5PSEQvF2=	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
Daoy	Mme0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHzj[mRKSzVyPUGyMlQ2PDJizszN	NF\jbIY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
ABC-1	NWfMNWY{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVXM[nQzUUN3ME2xNk4{PDFizszN	M2fyVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
KS-1	M3;MUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmCyTWM2OD1zMj6yPFMzKM7:TR?=	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
JAR	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEXZeWZKSzVyPUGyMlM{PjlizszN	M2[0NVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
CAMA-1	MorPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Moi0TWM2OD1zMj6xOlM{KM7:TR?=	NGjqSWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
U-118-MG	M3jTdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnHSTWM2OD1zMj6yOFQyKM7:TR?=	NFq1UHY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
OE19	NIKxO\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGC4blBKSzVyPUGxMlk{PjdizszN	NIrDUJA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
Mo-T	Mk\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1\0WWlEPTB;MUGuPVU1OSEQvF2=	NWrBcJRxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
SCC-9	MljtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX3JR\|UxRTFzLkixOVEh\|ryP	M3rieVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
HOS	NGnaPZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVTJR\|UxRTFzLki2PFMh\|ryP	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
UM-UC-3	M3j1bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3HOVmlEPTB;MUGuO\|QzOSEQvF2=	M{jJR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
MMAC-SF	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{[5fWlEPTB;MUGuO\|I2OiEQvF2=	NGTaclE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
MLMA	NVLrTVV7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NY\ZV\|JkUUN3ME2xNU43QTl5IN88US=>	MkH0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
RPMI-7951	NIHK[IxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYPJR\|UxRTFzLk[zOFgh\|ryP	NGXxUHQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
NCI-H1299	MnrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3Ll[2lEPTB;MUGuOlY1PyEQvF2=	MofYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
LS-411N	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEXEOGVKSzVyPUGxMlYyODFizszN	M3rMRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
HCC1954	NIfJcXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWnJR\|UxRTFzLkSzOkDPxE1?	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
GOTO	MmnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFXiUFZKSzVyPUGxMlUzODZizszN	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
FTC-133	Mni4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGO2XnpKSzVyPUGxMlMxQDFizszN	M2n6V\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
LB831-BLC	NGTmNlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGC5TVFKSzVyPUGxMlI2PTZizszN	MnfPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
HCC38	M4LqWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3HBdGlEPTB;MUCuPVcyPiEQvF2=	MoH2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
SF-295	NU\PVlJsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXPJR\|UxRTFyLkm5NFIh\|ryP	NGPNSlE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
K-562	MoL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYXqblFuUUN3ME2xNE45Ozl3IN88US=>	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
SW900	MoPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlrXTWM2OD1zMD64NlI5KM7:TR?=	NHPw[mI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
D-336MG	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHfWfoJKSzVyPUGwMlcxODVizszN	NVjtdVNURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
LXF-289	M1;p[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4jIZmlEPTB;MUCuO\|k3PyEQvF2=	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
SW962	NX;nW21QT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYizWmFqUUN3ME2xNE43OjB2IN88US=>	NXzaepdjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
VMRC-RCZ	M3fEcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3H4TmlEPTB;MUCuOlc1QSEQvF2=	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
HEC-1	NWDFRmwxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF7m[45KSzVyPUGwMlQxQDFizszN	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
A2058	MljzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYnU[2hVUUN3ME2xNE42PDlzIN88US=>	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
K5	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHLzWHZKSzVyPUGwMlM{QTVizszN	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
U031	NHf1N4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkLYTWM2OD1zMD6yOlg3KM7:TR?=	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
YH-13	M1P4bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{n2Z2lEPTB;MUCuN\|A2PyEQvF2=	Mlm3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
SK-UT-1	NUKxWm1GT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3HX[mlEPTB;MUCuNlU4PCEQvF2=	M{TyXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
NCI-H810	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUC4[3JHUUN3ME2xNE4yPTl5IN88US=>	M2HWdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
DJM-1	M4nIUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2myfmlEPTB;MUCuNVc{OiEQvF2=	NEG3RW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
CAL-51	M33IUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2rOXGlEPTB;MUCuNFg4PyEQvF2=	NIHHVIQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
HCE-4	NYLZcXhxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlXFTWM2OD1zMD6xNVIzKM7:TR?=	MmHKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
NCI-H2342	NVjre2xVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnPlTWM2OD1zMD6wNVU2KM7:TR?=	NIHZeo09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
A204	M3;6PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEi2dmRKSzVyPUGwMlA1PjZizszN	M3z5SFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
NCI-H1355	M2jtVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYjsNGFVUUN3ME25Mlk1ODh6IN88US=>	NEnETZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
SW837	NWLPTphtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoPPTWM2OD17Lki0PFIh\|ryP	NH7JdJM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
OCI-AML2	MlSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVPJR\|UxRTlwOE[5OkDPxE1?	Mn20QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
EFO-21	MlnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mk\jTWM2OD17LkW4O\|M2KM7:TR?=	NVTTUoVqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
C32	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXTJR\|UxRTlwNkOzOEDPxE1?	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
KP-4	NFHXXHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUTqdIxGUUN3ME25MlQ5QDN6IN88US=>	NXS1dFh1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
A101D	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M13uRWlEPTB;OT61NVcyQSEQvF2=	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
IA-LM	NHztOHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlLZTWM2OD17LkSxPVY3KM7:TR?=	Moi5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
HPAF-II	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mnf1TWM2OD17LkKyOVE5KM7:TR?=	NEXHWYo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
Capan-2	NGL1eJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVfJR\|UxRTlwNECxNFkh\|ryP	NWr6b3lFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
BFTC-909	NXvRb2ltT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mne3TWM2OD17LkG4Nlk4KM7:TR?=	NInRc2s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
RPMI-8226	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYLJR\|UxRTlwMUGzNFQh\|ryP	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
ChaGo-K-1	NHHJdXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWm0WWp1UUN3ME25MlExPTd7IN88US=>	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
NCI-H2228	NHzxb4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MonGTWM2OD17LkGxNFgyKM7:TR?=	M4PHfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
NCI-H226	M{fDRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1m1SmlEPTB;OT6wPUDPxE1?	NVfWSXNURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
D-566MG	NV;lUXQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYHJR\|UxRTlwMEG4NUDPxE1?	NXL5fVJKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
LS-1034	NU\vNZhqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH\pZ4FKSzVyPUiuPVQ3PTJizszN	Mk\XQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
NCI-H1792	MlT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFf0ZlFKSzVyPUiuPFg6ODNizszN	NIfLUZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
COLO-792	Mn3TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnfwTWM2OD16Lke0PVQ3KM7:TR?=	NFzlcm49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
A673	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mmj2TWM2OD16Lk[3OlEyKM7:TR?=	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
D-392MG	NF34UmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF21flVKSzVyPUiuOlYzOTRizszN	NUWxU3pPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
EGI-1	MlT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGPP[YtKSzVyPUiuOlAxQDhizszN	NVzkdYxHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
TGBC11TKB	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2PBRmlEPTB;OD60OlE3PCEQvF2=	NFrGRYQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
5637	M33OUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUiwWW0xUUN3ME24MlMyODV3IN88US=>	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
KYSE-70	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4TDNmlEPTB;OD6xPVc3OSEQvF2=	NFWzOnU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
VM-CUB-1	NX:ydItYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2HWZ2lEPTB;OD6xO\|AzQSEQvF2=	Mme0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
AM-38	NHXKOnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3;L[GlEPTB;OD6xOlI5KM7:TR?=	MojMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
NCI-H661	NGLiUIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4T1cmlEPTB;OD6wOVg3PyEQvF2=	M{PvOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
SHP-77	NYXo[po1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NELqRllKSzVyPUeuPFY3PTNizszN	M{Gxc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
DK-MG	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUfJR\|UxRTdwOEOyNFEh\|ryP	NGf5TYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
NB13	M33HS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{LoeWlEPTB;Nz64NlY3PyEQvF2=	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
COLO-829	M1PL[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NI\oTZdKSzVyPUeuOlY1PjNizszN	NGTIRYk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
OS-RC-2	NUfZSYVDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1P2TWlEPTB;Nz60PVg6PCEQvF2=	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
HCC1419	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUjvU5R3UUN3ME23MlQ3QDN\|IN88US=>	NHrod5Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
SKG-IIIa	NVLZPI9VT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIfRe2xKSzVyPUeuOFU{QDFizszN	NF[wR\|c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
COLO-668	M1LafWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXvxZmdiUUN3ME23MlQ{QTZ5IN88US=>	M3ToWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
CAL-62	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHvzVWZKSzVyPUeuN\|k5PjZizszN	NUnFT4RlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
HEL	NXPqbWJxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXTnOZEyUUN3ME23MlM4PTJzIN88US=>	MorlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
NCI-H2030	NGLSfXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWTPdFZvUUN3ME23MlM{Pjl6IN88US=>	Mm\pQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
DMS-114	NGrKPIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mmj0TWM2OD15LkK5OlMyKM7:TR?=	M4PuO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
NOS-1	NYPhd\|VTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWPJR\|UxRTdwMkW4Nlgh\|ryP	MlvtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
KP-N-YS	MnjKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVXJNJF5UUN3ME23MlE5OTRizszN	NVPubHZFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
OVCAR-4	MmLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWjJR\|UxRTdwMUWzOUDPxE1?	NGHLZng9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
NCI-H2405	M{f5PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH7YRW5KSzVyPUeuNFg{QTNizszN	NHuxbHQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
TE-11	NHrVfZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mmj3TWM2OD15LkC0PVY4KM7:TR?=	NF7ObW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
KLE	M3nxXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYjJR\|UxRTZwOU[1NVYh\|ryP	MlX3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
A388	NYqwOWxOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3S0V2lEPTB;Nj64PVUzKM7:TR?=	NVf3ZmNZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
NB12	M1:4cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYPJR\|UxRTZwN{i0NFQh\|ryP	NVvBOHdnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
PFSK-1	NGfTVZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3rDSmlEPTB;Nj63N\|Q4QCEQvF2=	M4fselxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
SK-HEP-1	NX3JSY94T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mkj6TWM2OD14LkexO\|U{KM7:TR?=	NELzNYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
Calu-3	MojJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXK5fYpjUUN3ME22MlY2PTZ6IN88US=>	NEe2T209[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
SH-4	M37hWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHH3eYxKSzVyPU[uOVg5PDRizszN	M125O\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
GCT	NXjmWXIxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVXJR\|UxRTZwNUOzPFch\|ryP	M3XjUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
MSTO-221H	NXHaeWFNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NG\J[IRKSzVyPU[uOVEyPyEQvF2=	MlTBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
GAMG	M1LNSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWrkXZZJUUN3ME22MlUxPjJizszN	M4LvV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
CAL-120	NVr6U5BtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWfCN\|YzUUN3ME22MlQ2OTZ{IN88US=>	NEDZfpY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
VA-ES-BJ	NFLMOYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2q4cGlEPTB;Nj6zNFQ3OiEQvF2=	MlHGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
SK-MEL-28	M2r2bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFnySW9KSzVyPU[uNlA6PjdizszN	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
8-MG-BA	NHOzWZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mlv5TWM2OD14LkG5N\|c6KM7:TR?=	NHLiNJA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
L-428	Mn76S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIT1NWtKSzVyPU[uNVgxOzdizszN	MknTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
Mewo	MnzYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGnWXoFKSzVyPU[uNVE1QDdizszN	M2H6VlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
RCM-1	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVzS[GV5UUN3ME22MlA4PzF7IN88US=>	M{fBblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
KE-37	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUfJR\|UxRTZwMEeyOVgh\|ryP	M{jWeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
TE-10	NVP6O5JRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mly4TWM2OD14LkC0PFM{KM7:TR?=	NV3jWphlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
HDLM-2	NFrJUZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHGxUIxKSzVyPU[uNFE1QDlizszN	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
CAKI-1	NVuyOmY4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXzJR\|UxRTZwMEC5PFUh\|ryP	MmjZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
RT-112	NXXuNppUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGLTe4ZKSzVyPUWuPVAzPDVizszN	NXHZXZlkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
HCC2998	NGXh[45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1iyRWlEPTB;NT63NVg4PyEQvF2=	NWC3ZWNFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
HCC1187	M3LnXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mlu2TWM2OD13LkexNFMzKM7:TR?=	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
HD-MY-Z	M3T1XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV6zZ201UUN3ME21MlY5PThzIN88US=>	Mn3kQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
RMG-I	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3G0eGlEPTB;NT62OVk1OiEQvF2=	NXLZdIgyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
BFTC-905	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX7JR\|UxRTVwNkW4O\|gh\|ryP	MmPuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
SW1990	NFjZO3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml7LTWM2OD13Lk[yNlg2KM7:TR?=	NI\RSYs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
SW13	MnjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkTrTWM2OD13LkWzNlY2KM7:TR?=	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
AGS	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkTvTWM2OD13LkS5OlE5KM7:TR?=	NHjwVpU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
ATN-1	NX7sV\|dKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUTJR\|UxRTVwNEGxPFQh\|ryP	MlvJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
CGTH-W-1	MkfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYnubFhLUUN3ME21MlM5PTh2IN88US=>	M{PGUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
NOMO-1	M4HzdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXHIPYUzUUN3ME21MlI{OTd4IN88US=>	Mnj5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
ALL-PO	Mnf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1Hje2lEPTB;NT6yNlU5PyEQvF2=	MkjzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
KP-N-YN	MmnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2CyTmlEPTB;NT6xNlU6OSEQvF2=	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
NCI-H1838	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1jtWmlEPTB;NT6wNlA4PiEQvF2=	M4fkdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
TE-9	Mnf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWXJR\|UxRTVwMEG1NlUh\|ryP	NIDFOZI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
KOSC-2	MmrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2P1V2lEPTB;ND65PVk2QSEQvF2=	NGfybJI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
ES1	NGPLfXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkLPTWM2OD12Lkm2NFM2KM7:TR?=	NYnXNJlERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
KNS-62	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoPDTWM2OD12LkmwPFA4KM7:TR?=	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
KYSE-520	M3zTUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYXJR\|UxRTRwOEiwNVgh\|ryP	NWHIeI9[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
P30-OHK	MkjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXPXXHJOUUN3ME20MlgyQTJ7IN88US=>	NHvaUnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
NB10	NXixcnI2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEm4[pVKSzVyPUSuOVk4QDFizszN	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
A172	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGPtS2JKSzVyPUSuOVU2OjFizszN	M{OxflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
SK-OV-3	NFTCW5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFW3R\|NKSzVyPUSuOFYxPDJizszN	NUHKTow{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
GR-ST	NEL0WZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF:3TXFKSzVyPUSuOFMyQCEQvF2=	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
HCC1937	NXHTXJluT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVi0TJNMUUN3ME20MlM4QTl\|IN88US=>	M3LZVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
LU-139	M33wNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVrJR\|UxRTRwM{eyOFch\|ryP	M3;4clxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
SNU-C2B	M2O4dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NITPNnRKSzVyPUSuN\|Q3QDZizszN	Mlv4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
KARPAS-299	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVzlb\|FGUUN3ME20MlMyODF\|IN88US=>	M1rFW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
EW-11	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH[0bG9KSzVyPUSuNVMzPjFizszN	NX7yVGZRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
HL-60	NEnyUpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV\m[FR{UUN3ME20MlEzOjRzIN88US=>	NEnX[GU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
TCCSUP	M{XOWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2XNW2lEPTB;ND6xNVA2KM7:TR?=	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
RCC10RGB	MlPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXHJR\|UxRTRwMEGyOFYh\|ryP	M3PZR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
NCI-H441	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXjueVg6UUN3ME2zMlk4ODF2IN88US=>	NGTaNGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
EW-16	M1Hsfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NI\SSmtKSzVyPUOuPVU2PzdizszN	M1L2eVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
JVM-2	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUnJR\|UxRTNwOUS3OVIh\|ryP	NILUcHk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
NH-12	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV[1V\|JoUUN3ME2zMlk1OTh5IN88US=>	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
IST-MES1	NGLXO4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVjGUFZ2UUN3ME2zMlk1ODJ7IN88US=>	M2f2OVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
NCI-H69	M2nVemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXfJR\|UxRTNwOUCxO\|gh\|ryP	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
KURAMOCHI	NF7MTHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4HJeGlEPTB;Mz64OlA2PiEQvF2=	NGLwV5E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
NCI-H1155	MoW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVHSRlJHUUN3ME2zMlg1OTV7IN88US=>	M{HNNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
NCI-H28	NVTGd3FHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4nRSGlEPTB;Mz64Nlk3OSEQvF2=	NFHoSmU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
ES4	MlfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXi5SVhoUUN3ME2zMlgzOjh4IN88US=>	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
J-RT3-T3-5	NFHvN2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWnJR\|UxRTNwN{W0NFYh\|ryP	NF\KVFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
PANC-10-05	M1zobGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFjCRYlKSzVyPUOuO\|IxPzJizszN	NVe4Tmg4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
SK-MES-1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnHhTWM2OD1\|Lk[0OlE1KM7:TR?=	M1vUNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
C2BBe1	NXr6Nml1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFzEbopKSzVyPUOuOlQ1ODdizszN	MnX0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
A2780	NFjWfoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVTJR\|UxRTNwNkSwPFkh\|ryP	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
CaR-1	NED0XZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF7aTWJKSzVyPUOuOlExPDhizszN	NYnBZo1FRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
SK-LU-1	M1PFZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHe1XmRKSzVyPUOuOlA3PDVizszN	NWHEUoQ1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
OAW-28	M4XGeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkPTTWM2OD1\|LkW5OFI3KM7:TR?=	NXfjNHlxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
TE-1	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVnJR\|UxRTNwNUmxOlkh\|ryP	NFrPOm89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
639-V	M3fiNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF;qcIJKSzVyPUOuOVc4QTJizszN	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
C8166	NEjxfFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWHJR\|UxRTNwNE[1NlEh\|ryP	NVTST4x{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
NTERA-S-cl-D1	NXfXVHRWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVS5bmt5UUN3ME2zMlQ1QTV5IN88US=>	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
D-542MG	MlHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIjMW5JKSzVyPUOuOFQzOjJizszN	MmmxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
LB771-HNC	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlnNTWM2OD1\|LkO5NVI3KM7:TR?=	MlnhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
NCI-H727	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkLhTWM2OD1\|LkO4OVg1KM7:TR?=	NFfO[mM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
SW1463	MkD1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUTlR2xyUUN3ME2zMlI3OTl{IN88US=>	M1S4XlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
NCI-H1793	MmHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoTZTWM2OD1\|LkKxNFk5KM7:TR?=	M1TOS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
HT-1376	NXHLSYw4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml3wTWM2OD1\|LkKwOVA3KM7:TR?=	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
647-V	NIj6SZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3fwZWlEPTB;Mz6xOlIzKM7:TR?=	NXH4RWFwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
BCPAP	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlvtTWM2OD1\|LkC4Nlk2KM7:TR?=	NWrBZ25CRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
MN-60	NYD4TGJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH\Zb4xKSzVyPUOuNFQ6PzRizszN	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
COLO-680N	NWX1ZXVKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXP0ToJ{UUN3ME2zMlAxPDl3IN88US=>	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
DU-4475	MmTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmPMTWM2OD1{Lkm5NFUzKM7:TR?=	M4\YcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
NCI-H1693	NIfCRVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWPHeXhlUUN3ME2yMlk2QDl5IN88US=>	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
HC-1	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1S4WmlEPTB;Mj65OFAyOiEQvF2=	MoL5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
KYSE-510	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M33NTGlEPTB;Mj64Olc5PiEQvF2=	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
OVCAR-3	MoG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MW\JR\|UxRTJwOEW1PVQh\|ryP	NF7XboM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
PC-3	NVfGeFBDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVzJR\|UxRTJwOEOzNVch\|ryP	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
BB65-RCC	Ml\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M133TWlEPTB;Mj64NFcyOyEQvF2=	NUXEfZd7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
QIMR-WIL	NWLkVmlxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV3JR\|UxRTJwN{W5OVIh\|ryP	NXvYZ4JLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
HuP-T4	MkH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYfJR\|UxRTJwN{K4NVgh\|ryP	NHXnRYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
Detroit562	MmD1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4HTN2lEPTB;Mj62PVg1PSEQvF2=	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
DMS-79	MmD0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYXxTmhTUUN3ME2yMlY6Ojh2IN88US=>	M3W4TFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
MC-IXC	NEj5Um5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWrBVpdrUUN3ME2yMlY1PDV\|IN88US=>	NFG1XWQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
TE-8	MnnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVy1emt[UUN3ME2yMlY{PjV\|IN88US=>	M4nRfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
MKN7	M3jQU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHXk[\|RKSzVyPUKuOlI4PDhizszN	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
HH	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYrJR\|UxRTJwNEm4OVQh\|ryP	NHT4bos9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
CFPAC-1	NFntfmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlrkTWM2OD1{LkSzPFY1KM7:TR?=	NV64OZdLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
HTC-C3	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3nEe2lEPTB;Mj60NlI3PyEQvF2=	NVXNdVczRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
NY	NWT5WlhwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MljSTWM2OD1{LkO3Nlch\|ryP	M2noRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
KU812	NX;ESHFKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVjVZmJTUUN3ME2yMlM3Pzd7IN88US=>	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
EW-18	MmK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVnJR\|UxRTJwM{W0O\|Eh\|ryP	Mn6wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
NCI-H2170	MlLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEnodVhKSzVyPUKuN\|Q4QDNizszN	M3jvWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
JVM-3	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUX3eGhwUUN3ME2yMlM1PjR\|IN88US=>	M2eyOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
IGROV-1	MnfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlPNTWM2OD1{LkOxNlM4KM7:TR?=	MoPvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
A498	Ml3BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUS4dYNnUUN3ME2yMlI6PDF3IN88US=>	MkLTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
BT-20	NHrhV5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NU[3SnIzUUN3ME2yMlI3PzR2IN88US=>	M{PrdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
SCC-4	MkPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4LDU2lEPTB;Mj6yNVc4PiEQvF2=	NXnHfWQ4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
786-0	NHeydpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEDSboJKSzVyPUKuNVg1ODZizszN	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
RXF393	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFflbW5KSzVyPUKuNVMxOzZizszN	Ml:4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
KARPAS-45	NFPJVWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2G2R2lEPTB;Mj6xNlQ4QSEQvF2=	NYHUdJlIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
RPMI-8866	MlnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYrafmhOUUN3ME2yMlA5PDhzIN88US=>	NWjpOVAzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
NCI-H2009	MlToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlrWTWM2OD1{LkC2NlE1KM7:TR?=	NF35TIM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
SW1116	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX73[FNqUUN3ME2yMlA3ODB7IN88US=>	NYTtdZBoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
EKVX	NIPi[FhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWS5eIJ4UUN3ME2yMlA1QTN7IN88US=>	NGKzWYk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
TGBC24TKB	M{f6c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mk\ITWM2OD1{LkCyPVYyKM7:TR?=	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
CAL-12T	MmnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NELUWZJKSzVyPUKuNFE5PjFizszN	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
HCC70	MnzyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml7jTWM2OD1{LkCwPFE2KM7:TR?=	NGnle3Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
OMC-1	MlPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWLqVZZRUUN3ME2xMlk6QDh6IN88US=>	NUCwOndmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
EPLC-272H	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2P3TGlEPTB;MT64OVU1QSEQvF2=	M1[zVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
NCI-H209	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3vkXGlEPTB;MT63O\|I3QSEQvF2=	NHH4Z449[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
NCI-H1666	MlX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVS5[nI4UUN3ME2xMlc1PzB2IN88US=>	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
COLO-678	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFzaelZKSzVyPUGuO\|M1PDRizszN	NX\W[\|dpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
PANC-03-27	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1f6UGlEPTB;MT63NFE{QSEQvF2=	MoXBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
BB30-HNC	NED6XJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUTJR\|UxRTFwNki5O\|Ih\|ryP	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
ML-2	MlL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3[wOmlEPTB;MT62OFAzQSEQvF2=	M{\P[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
BT-549	NIrrbXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3HkNGlEPTB;MT61PFc1PyEQvF2=	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
HSC-3	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUfJR\|UxRTFwNUSzPEDPxE1?	NG\0O3g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
LAMA-84	NEDvNmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXfJR\|UxRTFwNUO4NVUh\|ryP	M4T6R\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
SCC-25	NHj3Z45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXH5So01UUN3ME2xMlUzOzJ{IN88US=>	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
SAS	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYLRTZI2UUN3ME2xMlUyPjJ{IN88US=>	NHr3NmY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
BE-13	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2[4TGlEPTB;MT61NFY4OSEQvF2=	NYPTe2o2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
J82	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVvJR\|UxRTFwNEW3OlYh\|ryP	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
697	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWHJR\|UxRTFwNESxNFQh\|ryP	NY\lVmNlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
NCI-H526	M2rlNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3O3bmlEPTB;MT60N\|gzPiEQvF2=	M1P6eVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
RH-1	NH6xc5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF:2PFRKSzVyPUGuOFEyOzZizszN	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
CCRF-CEM	NYfSV4U3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NITXTJdKSzVyPUGuOFEyOSEQvF2=	M2DxVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
NB5	M2HRe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1rNSmlEPTB;MT60NFg6PCEQvF2=	MnSyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
KMOE-2	M2fvT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlXuTWM2OD1zLkO5PFE2KM7:TR?=	M17MdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
SK-N-DZ	M4G3WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1zrbGlEPTB;MT6zOlk1PyEQvF2=	M3jRcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
SW48	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV3JR\|UxRTFwM{[2NVgh\|ryP	NI\tPXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
SW954	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1[2S2lEPTB;MT6zOFA1QCEQvF2=	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
NCI-H1650	NIfEeotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVnoeXlZUUN3ME2xMlM{PDh{IN88US=>	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
NKM-1	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWW2ZotuUUN3ME2xMlMzPTl5IN88US=>	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
NCI-H1092	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkLKTWM2OD1zLkOwPFUh\|ryP	M4jCdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
CTV-1	NHPaUGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlTCTWM2OD1zLkOwPEDPxE1?	NF3MRXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
GCIY	Mm\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NULvOW15UUN3ME2xMlMxOTN{IN88US=>	NXjM[5hYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
SW1088	NWP2SXR{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{ThV2lEPTB;MT6yPVYxPyEQvF2=	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
769-P	NU[0NnNPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYnJR\|UxRTFwMke5NVgh\|ryP	NFzCT5c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
OAW-42	MoTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGfjSYRKSzVyPUGuNlc5OjVizszN	M4HEN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
SNU-449	M4XlXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVrIN4RwUUN3ME2xMlIzOjB6IN88US=>	M4WwS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
MKN1	NYjaNoh3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoDZTWM2OD1zLkKxPVg4KM7:TR?=	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
NCI-H1648	MorKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUPreWp7UUN3ME2xMlExPjF4IN88US=>	NWHNenBoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
KU-19-19	NIfNTYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NECzU2pKSzVyPUGuNFg2PDFizszN	MkT5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
MHH-PREB-1	NWTl[It4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVTJR\|UxRTFwMEi0OVEh\|ryP	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
EM-2	Mme0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkjLTWM2OD1zLkCzNFE3KM7:TR?=	NHfqNIs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
NCI-H1304	MnjnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnTTTWM2OD1zLkCxOlQ{KM7:TR?=	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
DOHH-2	NGrscGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{fXOmlEPTB;MT6wNFAzOSEQvF2=	NWPhRW9bRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
MS-1	MmfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV7o[\|BtUUN3ME25PVQvPjlibl2=	NU\oO2F4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
SK-NEP-1	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{LUfmlEPTB;OUi5MlQ1KG6P	NXX5c3JxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
HT-3	Ml7SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlPOTWM2OD17OEKuOFEhdk1?	MkTYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
BHY	MoDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVPCSIJpUUN3ME25O\|UvPDhibl2=	M4\SN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
BT-474	NFj5cmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnvZTWM2OD17M{iuNVQhdk1?	MkXFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
CAPAN-1	M{jBdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2DifmlEPTB;OEizMlI6KG6P	NXjXTpp4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
NCI-H2126	NXzWc4VUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXfJR\|UxRTh6Mj64N{BvVQ>?	NYS4cGl6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
COR-L88	NVHwbVZlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmnhTWM2OD16OEKuNlYhdk1?	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
DEL	NYjhToNtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXLJR\|UxRTh5Nz62OUBvVQ>?	MmHEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
AU565	M1PLdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUHaVXV{UUN3ME24OlkvPiCwTR?=	NHfMSWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
23132-87	M4XLSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUHJR\|UxRTh4ND6yPEBvVQ>?	MlW3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
LoVo	M2T6VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVfuclllUUN3ME24OVkvODZibl2=	NYPjcnZYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
TE-12	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEPPXIVKSzVyPUiyNU4yOSCwTR?=	M4LGWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
EC-GI-10	NXfLVHpST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFzv[YhKSzVyPUe4PE42OiCwTR?=	NWDiWpZLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
LU-135	NVLIU\|dNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVLJR\|UxRTd6Mz6wN{BvVQ>?	NYWy[Gp[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
A431	M3mwSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUTEOHN[UUN3ME23PFAvODRibl2=	NGq0OJU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
TE-6	NGjXUm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV;JR\|UxRTd4ND6zNUBvVQ>?	M1Lj[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
COLO-684	NIPa[ZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1PQTWlEPTB;N{WzMlAyKG6P	NYnOTIxiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
HAL-01	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEm2S\|RKSzVyPUezOE44OSCwTR?=	M4fzOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
NCI-H1770	M{PQOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYjJR\|UxRTd{Mj60JI5O	M2rJXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
LU-134-A	NIrvSIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXnJR\|UxRTdzOT6wPUBvVQ>?	Mnu2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
L-363	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEW3NIxKSzVyPU[3NU46PCCwTR?=	M1;3VFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
ETK-1	MmWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NImyWVFKSzVyPU[2Nk42QSCwTR?=	MlfrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
COR-L105	NFK2e5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWDJR\|UxRTZ4Mj61N{BvVQ>?	M1\XUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
NBsusSR	M3zsUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUfJR\|UxRTZ2Nj61NkBvVQ>?	M4fwPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
ME-180	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEfm[nZKSzVyPU[zNk46KG6P	M3juXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
DBTRG-05MG	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXrJR\|UxRTZ\|Mj6yPEBvVQ>?	NEPNTY49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
MV-4-11	M2i0R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3jQZmlEPTB;NkK3Mlchdk1?	NUD6c5NYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
LB1047-RCC	Mlj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYPJR\|UxRTZ{NT6yPUBvVQ>?	NFrubHM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
Ramos-2G6-4C10	M3zQSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHLONYRKSzVyPU[yNU41PiCwTR?=	M{nQR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
NB69	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGrxUGlKSzVyPU[xOE4{PSCwTR?=	MmnFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
FADU	M{PxR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFrt[YtKSzVyPU[wOE43QSCwTR?=	NITyNmY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
NCI-H1623	NG[5eGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M13u[mlEPTB;NUm5MlM3KG6P	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
CAL-39	M3HPWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIjLPIVKSzVyPUW5Ok4{KG6P	NIPtXoY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
Ca9-22	NVL4WYNET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGf6cmlKSzVyPUW4PE43PCCwTR?=	M3L4OlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
CAN	MnXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVTJR\|UxRTV6MD63OkBvVQ>?	M4X3UFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
RS4-11	NWr3RpFiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV3JR\|UxRTV4OD61PUBvVQ>?	Mn3rQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
DSH1	M3XzW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF3JSlFKSzVyPUW2Ok45QCCwTR?=	NI\KUWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
NB7	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVPJR\|UxRTV2Nj6zNkBvVQ>?	M1f4TlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
NCI-H82	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUjJR\|UxRTV2MD61JI5O	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
KYSE-180	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnvDTWM2OD13M{CuOlIhdk1?	M2P6[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
NCI-H358	NV;kd2FNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX3vS\|hOUUN3ME21NlcvPjZibl2=	NVXmRopTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
SCC-15	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml;UTWM2OD13MkWuOlghdk1?	M4nBOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
HN	Mn;LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHqwfZBKSzVyPUWxO{4{QCCwTR?=	NUO0N21RRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
TK10	MmLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFrNXItKSzVyPUWxOU4yOSCwTR?=	NGL0Zlk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
MOLT-13	NXizOYhUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1HwemlEPTB;NUG0MlgzKG6P	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
SK-MEL-1	NEW3XHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1eyc2lEPTB;NUGwMlk6KG6P	NHKxfVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
HO-1-N-1	NEn2dXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlraTWM2OD13MEmuNlUhdk1?	M2TRTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
KYSE-270	NXLBbmxyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlG2TWM2OD12OUiuOlUhdk1?	MorvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
BPH-1	M1rXemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV3zNlFwUUN3ME20PVEvOTZibl2=	NHfPTGE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
EFO-27	NE\2WXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4TodGlEPTB;NEW0Mlc1KG6P	NYrNWXh1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
DoTc2-4510	M2\Wd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV\me5dWUUN3ME20OFIvOTJibl2=	M1exZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
CTB-1	M1\lUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX\JR\|UxRTR{ND60JI5O	M1jkcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
KY821	M2G3eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2rZZ2lEPTB;NEC4MlU4KG6P	M2\6NFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
NUGC-3	M4r6Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlfFTWM2OD12MEGuPFEhdk1?	Mlm4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
MDA-MB-175-VII	M4HZXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX\wPHlQUUN3ME2zO\|gvQDhibl2=	MmrXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
CAL-33	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFLRXpVKSzVyPUO3NE46KG6P	NVTwTVdDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
KASUMI-1	NF7RWZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUG0V4U3UUN3ME2zOlYvPzNibl2=	NHvzNXo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
ECC10	NF\vXFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mlv4TWM2OD1\|NUKuPVYhdk1?	NXLzb2dGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
A4-Fuk	Ml\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3O4bmlEPTB;M{WwMlAzKG6P	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
SK-MEL-24	Mn7PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV3JR\|UxRTN\|Nz64O{BvVQ>?	M{LNTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
HCC1806	NYP1XFJCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEH1OolKSzVyPUOzO{42OSCwTR?=	NGLuOpg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
PC-14	M2eybmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUTwRWNvUUN3ME2zN\|MvPDFibl2=	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
ACHN	MlXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MY\JR\|UxRTN\|MT60JI5O	NWnaVlFyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
P12-ICHIKAWA	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVnJR\|UxRTN{OD6wOkBvVQ>?	NF3Hemc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
TI-73	NFzMTG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUnjS5cxUUN3ME2zNVIvPzVibl2=	M4\qXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
CAL-54	MmLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFvFSFdKSzVyPUOxNU4zOyCwTR?=	M{[5PFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
SBC-1	MlG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF;YVIhKSzVyPUOwO{44QSCwTR?=	NVHHc4VNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
BALL-1	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX\JR\|UxRTJ7Nz60NkBvVQ>?	NIC3[Gc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
CAL-27	MoTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXzUZ2NoUUN3ME2yPFkvODhibl2=	NFnoUoc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
NCI-SNU-1	Mn3xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYjJR\|UxRTJ6Mz6zNkBvVQ>?	NFS4V4Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
HCE-T	M3nsSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVzPfmdzUUN3ME2yO\|kvPzlibl2=	NIPBfFk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
MEG-01	NXO4OHZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnT4TWM2OD1{N{[uO\|Yhdk1?	MlPVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
CAL-72	M1vOdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWLnPIZlUUN3ME2yOlgvPzNibl2=	NYT5PVA2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
KYSE-450	NXfzOlYzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4[xTmlEPTB;MkS3MlkzKG6P	M3P6VFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
EW-13	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1zhU2lEPTB;MkK1MlEhdk1?	NH7rNYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
DU-145	MnjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXHHd4c4UUN3ME2yNVkvODRibl2=	MoDiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
KYSE-140	M1riT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHzVOoRKSzVyPUKwPU46PiCwTR?=	M3rCOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
CHL-1	MnWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVfJR\|UxRTJyOD61NUBvVQ>?	MmfHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
KG-1	MnTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXzJR\|UxRTJyND6zOEBvVQ>?	NE\2TYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
LB2241-RCC	M2rISWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3XSUmlEPTB;MUm0Mlk{KG6P	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
BV-173	NXPtSphuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHuwcG9KSzVyPUG4Ok42PSCwTR?=	MnvEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
LU-65	NIL4NYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NELEeW5KSzVyPUG2Ok43OSCwTR?=	MonOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
HSC-2	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVrJR\|UxRTF4NT61O{BvVQ>?	NY[5XVR5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
NCI-H292	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX3JR\|UxRTF4Mj62OkBvVQ>?	M3fnZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
H9	NF\UZpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWjJR\|UxRTF\|Nz6yJI5O	MoXXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
DOK	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX\JR\|UxRTl\|Lk[yJI5O	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
HSC-4	NWLzVXh6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnToTWM2OD14MT61N{BvVQ>?	M1fXSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
DB	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGXnR5ZKSzVyPU[wMlk3KG6P	MoPrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
HuO-3N1	MojDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mm\QTWM2OD13Nj6wPUBvVQ>?	M3fjWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
HCC2218	NGHtR2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYjJR\|UxRTVyLkW5JI5O	NXP3d\|NFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
EW-3	NEns[FVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2PoOmlEPTB;NE[uNFQhdk1?	MoTVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
NCI-SNU-5	M2nEPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M164O2lEPTB;MkiuNVkhdk1?	M3L3O\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
NCI-H720	NIXZR2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoDyTWM2OD1{Nj65NkBvVQ>?	NIi1[5Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
EoL-1	NYjYW4llT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYrieGJDUUN3ME21MlE4KG6P	MkfXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
MIAPaCa2	M{\YR2Fxd3C2b4Ppd{BCe3OjeR?=	M4nuU\|IxKM7:TR?=	NY\ISI5VOjRiaB?=	MUnEUXNQ	MorJ[I9meyCwb4SgbY5lfWOnIHHwc5B1d3OrczDhd5Nme3OnZDDhd{Bk[XOyYYPlJFMh[WO2aY\heIlwdg>?	M3;5[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNE[2OVU2Lz5{MES2OlU2PTxxYU6=
MIAPaCa2	NFLmRY9CeG:ydH;zbZMhSXO\|YYm=	NWfmW291OTBizszN	NFrnW5AzPGhib4KgOFghcA>?	M4nZXmROW09?	Ml3i[I9meyCwb4SgbY5lfWOnIHHwc5B1d3Orcx?=	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODR4NkW1OUc,OjB2Nk[1OVU9N2F-
MIAPaCa2	M3;zPWN6fG:2b4jpZ{BCe3OjeR?=	NWfafmpsOSEQvF2=	MXixNEBl	NGL6WlhFVVOR	NXftR41mcGG\|IH7vJIN6fG:2b4jpZ4l1gSCjc4Pld5Nm\CCjczDzeZBxemW\|c3nvckBw\iClb3zvcpkh\m:{bXH0bY9v	NWftS2VJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC0OlY2PTVpPkKwOFY3PTV3PD;hQi=>
MIAPaCa2	NIiwfWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGDSSZUzNjVizszN	MmjYO\|IhcA>?	MXnEUXNQ	MUDoZZMhdm9iZ4Lve5RpKGmwaHnibZRqd25?	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODR4NkW1OUc,OjB2Nk[1OVU9N2F-
H1975	MmrrT4lv[XOnIFHzd4F6	MWCwMlUh\|ryP	NGfySJEzPCCq	NWfyVJdXTE2VTx?=	NVvVUGl3\G:nczDuc5QhcW6qaXLpeEBGT0[UIFy4OVhTN1R5OUDNJI12fGGwdD3t[YRq[XSnZDDBb5QheGixc4Doc5J6dGG2aX;u	NGrkdXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzPVM1Oid-MkKzN\|k{PDJ:L3G+
H1975	MXLLbY5ie2ViQYPzZZk>	M{HPTlAvPSEQvF2=	M1TCUFI1KGh?	MXzEUXNQ	NGSyTIlld2W\|IH7veEBqdmirYnn0JGVITlJiTEi1PHIwXDd7MF2gcZV1[W62LX3l[IlifGWmIFXyb{BxcG:\|cHjvdplt[XSrb36=	NYLJWIs1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzN\|k{PDJpPkKyN\|M6OzR{PD;hQi=>
H1975	NUDQepJ7U2mwYYPlJGF{e2G7	NX;mV48xOC5zMkWg{txO	NYfGZmJwOjRiaB?=	NH3nc4dFVVOR	NHvjZpRld2W\|IH7veEBqdmirYnn0JGVITlJiTEi1PHIwXDd7MF2gcZV1[W62IGmxNFY5KGG3dH;wbI9{eGixconsZZRqd25?	M3yx[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O5N\|QzLz5{MkOzPVM1OjxxYU6=
H1975	M4DVfmtqdmG\|ZTDBd5NigQ>?	M1\uSVAvOzNizszN	M3qwPFIhcA>?	MWXEUXNQ	NGm5cZZld2W\|IH7veEBqdmirYnn0JGVITlJiTEi1PHIwXDd7MF2g[I92[mynIH31eIFvfCCyaH;zdIhwenmuYYTpc44>	Mn3SQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzMkS4PVgoRjJ2MUK0PFk5RC:jPh?=
H1975	M3jlcmtqdmG\|ZTDBd5NigQ>?	NYKxW2tOOC5\|MzFOwG0>	M2PrZ\|IhcA>?	MmXxSG1UVw>?	NYfydFJ2\G:nczDuc5QhcW6qaXLpeEBGT0[UIFy4OVhTN1R5OUDNJIRwfWKuZTDteZRidnRiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKEWUSzDwbI9{eGixconsZZRqd25?	M{\IfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUK0PFk5Lz5{NEGyOFg6QDxxYU6=
H1975	MmP4T4lv[XOnIFHzd4F6	NHLreoIxNjN\|IN88US=>	NEWwUpQzKGh?	NHTEXlVFVVOR	MYXkc4V{KG6xdDDpcohq[mm2IFXHSnIhVDh3OGKvWFc6OE1iZH;1ZoxmKG23dHHueEBie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gRWtVKHCqb4PwbI9zgWyjdHnvci=>	MmPHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzMkS4PVgoRjJ2MUK0PFk5RC:jPh?=
HCC827	MWnLbY5ie2ViQYPzZZk>	M4XZXVAvOTFizszN	M2PXdlEhcA>?	MorYSG1UVw>?	MXPoZZMhdm9iaYLy[ZZmenOrYnzlJIlvcGmkaYTpc44hd2ZiRVfGVkBie3Onc4Pl[EBieyC{ZXPveoVzgSCxZjDFS2ZTKGG3dH;wbI9{eGixconsZZRqd25?	MmLuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzMkS4PVgoRjJ2MUK0PFk5RC:jPh?=
H1975	MXvGeY5kfGmxbjDBd5NigQ>?	NGT2fFIyKM7:TR?=	NWrmUJpxOjRiaB?=	NEi1dZBFVVOR	NYKxdFZJ\G:nczDuc5QhcW6qaXLpeEBGWkticHjvd5Bpd3K7bHH0bY9vKGmwIHj1cYFvKEhzOUe1JINmdGy\|IHjhdoJwemmwZzDFS2ZTKEx6NUjSM3Q4QTCP	MoDHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4MEe1PVEoRjJ2NkC3OVkyRC:jPh?=
H1975	NV3NN\|BpU2mwYYPlJGF{e2G7	M{PUTlEh\|ryP	M4TpcFI1KGh?	NX7NUWI2TE2VTx?=	MnzC[I9meyCwb4SgbY5pcWKrdDDFS2ZTKHCqb4PwbI9zgWyjdHnvckBqdiCqdX3hckBJOTl5NTDj[YxteyCqYYLic5JqdmdiRVfGVkBNQDV6Uj;UO\|kxVSCvdYThcpQ>	NELzbJI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[wO\|U6OSd-MkS2NFc2QTF:L3G+
LNCaP	Mne2SpVv[3Srb36gRZN{[Xl?	M1P5d\|ExKM7:TR?=	NGXVWGQzcCCxcjC0JIg>	NWHSSINFTE2VTx?=	NVi2S3hJ\G:nczDuc5QhcW6qaXLpeEBifXSxcHjvd5Bpd3K7bHH0bY9vKG:oIHntcZVvd3C3cnnmbYVlKG[uYXeteIFo\2WmIFLtfEBie3Onc4Pl[EBieyCrbnPvdpBwemG2aX;uJI9nKFt\|MmDdRXRR	NVzlcHBjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi2Olc{OTJpPkG4OlY4OzF{PD;hQi=>
A431	NGrUWXVMcW6jc3WgRZN{[Xl?	MmHLNUDPxE1?	NWiwbJNvOSCq	MY\EUXNQ	MWPoZZMhdm9iaYLy[ZZmenOrYnzlJIlvcGmkaYTpc44hd2ZiRVfGVkBifXSxcHjvd5Bpd3K7bHH0bY9v	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyMEW5OEc,OjR7MEC1PVQ9N2F-
NCI-H1975	M{TrfGZ2dmO2aX;uJGF{e2G7	NYTzbVBrOTBizszN	Mn3BPEBp	NUHs[YV1TE2VTx?=	NHf3W5Zld2W\|IH7veEBqdmirYnn0bUBGT0[UIHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiCHUlugdIhwe3Cqb4L5cIF1cW:w	M{\PPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MUG2NVY5Lz5{M{GxOlE3QDxxYU6=
HCC827	NH;lbFhEgXSxdH;4bYMhSXO\|YYm=	MmfWNE42KM7:TR?=	M1LKeFczKGh?	MXPEUXNQ	NGfCNIZp[XNibn:gZ5l1d3SxeHnjbZR6	NWDEb4FIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5PVM{OjhpPkKzPVk{OzJ6PD;hQi=>
HCC827	M1zsOmZ2dmO2aX;uJGF{e2G7	MoTuNE42KM7:TR?=	MWWyJIg>	NELVPZRFVVOR	NY[5V49k\G:nczDuc5QhcW6qaXLpeEBkNU2ndDDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIIC0OE81OiCyaH;zdIhwenmuYYTpc44>	MmrRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7OUOzNlgoRjJ\|OUmzN\|I5RC:jPh?=
HCC827	NGLM[3VHfW6ldHnvckBCe3OjeR?=	MVewMlUh\|ryP	M4\sclIhcA>?	NYPITYt5TE2VTx?=	M2PkSYRw\XNibn;0JIlvcGmkaYSgZ{1O\XRiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCDS2SgdIhwe3Cqb4L5cIF1cW:w	MmfMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7OUOzNlgoRjJ\|OUmzN\|I5RC:jPh?=
SW620	Mn\uR5l1d3SxeHnjJGF{e2G7		NInPOoo1QCCq	MX;EUXNQ	Mkm1TWM2OD1{OD6yJO69VQ>?	NI\hVnY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFU6PCd-MkS5NFA2QTR:L3G+
Sf9	NUP3UHpXU2mwYYPlJGF{e2G7		NGHGPI8yOCCvaX6=	NYX5ZpZ4TE2VTx?=	MlSwTY5pcWKrdHnvckBw\iCjdYTvdIhwe3Cqb4L5cIF1cW:wIH;mJJJm[2:vYnnuZY51KGircz30ZYdo\WRiRVfGVkAp[W2rbn:gZYNq\CB4NEWtNVE5PiliZYjwdoV{e2WmIIfpeIghUUN3MDDv[kAxNjB{IN88US=>	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd\|MUK4NUc,OjR5M{GyPFE9N2F-
HepG2	M37SW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NF7oS2wzPCCq	NISwZlZFVVOR	M3[xSWlEPTB;Nj60NkDPxE1?	NIHIWWM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEezNVI5OSd-MkS3N\|EzQDF:L3G+
Hela	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1O1OFI1KGh?	M4XuNGROW09?	MkflTWM2OD1{Lk[3JO69VQ>?	M2H0Z\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{OxNlgyLz5{NEezNVI5OTxxYU6=
NCI-H1975	M2rXcWZ2dmO2aX;uJGF{e2G7	M3vHPFExOCEQvF2=	M3vMbFE2OCCvaX6=	MkniSG1UVw>?	NHTxdGFKdmS3Y4Tpc44hd2ZiTl:gdJJw\HWldHnvckBqdiCqdX3hckBPS0lvSEG5O\|Uh[2WubIOgbIFz[m:{aX7nJGVITlJiTEi1PHIwXDd7MF2gcZV1[W62	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZyN{W5NUc,OjR4MEe1PVE9N2F-
BEAS2B	MmDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWCwRYpyPTBizszN	NWXObIV6PzJiaB?=	NVP6XoN1TE2VTx?=	NXuyZlNkUUN3ME2xN{46PCEQvF2=	MofyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4MEe1PVEoRjJ2NkC3OVkyRC:jPh?=
KB	MVjLbY5ie2ViQYPzZZk>	MUmxNEDPxE1?	NGnkW2wyKGh?	M3WxXmROW09?	MUnJcohq[mm2aX;uJI9nKEWJRj3zeIlufWyjdHXkJIF2fG:yaH;zdIhwenmuYYTpc44hd2ZiRVfGVkB4cXSqIFnDOVAhd2ZiMD6wNlUh\|ryP	M1XuS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEGxNVI{Lz5{NESxNVEzOzxxYU6=
Calu3	NFHFZmFEgXSxdH;4bYMhSXO\|YYm=		M1HhR\|czKGh?	M3;Q[mROW09?	NYnH[VlvS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hS2GudUOgZ4VtdHNiZYjwdoV{e2mwZzDISXIzKHerdHigTWM2OCCxZjCwMlk6KM7:TR?=	NGK2eHM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESxNVEzOyd-MkS0NVEyOjN:L3G+
A431	NGXpcYZEgXSxdH;4bYMhSXO\|YYm=		Mnf2O\|IhcA>?	M2LQ[2ROW09?	MX3DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOFMyKGOnbHzzJIV5eHKnc4PpcochTUeIUjD3bZRpKEmFNUCgc4YhOC53NTFOwG0>	M4j6W\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEGxNVI{Lz5{NESxNVEzOzxxYU6=
MDCK2	NUHKXlZbTnWwY4Tpc44hSXO\|YYm=	NFS2W5UyNjhizszN	MUi3NkBp	MnOzSG1UVw>?	MYXJcohq[mm2aX;uJI9nKGi3bXHuJGJEWlBiZYjwdoV{e2WmIHHzd4V{e2WmIHHzJGhw\WOqc4SgN\|M{PDJiYXPjeY12dGG2aX;uJJdqfGhiSVO1NEBw\iB\|LkG5JO69VQ>?	M1XCS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUi0NlE{Lz5{NEG4OFIyOzxxYU6=
MDCK	MlTCR5l1d3SxeHnjJGF{e2G7		NI[xNYg4OiCq	NEfYb4VFVVOR	Ml25S2k2OD1zLkS1JO69VQ>?	NEjse4I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG4OFIyOyd-MkSxPFQzOTN:L3G+
BCRP-MDCK2	MlnkSpVv[3Srb36gRZN{[Xl?	MoDnNU45KM7:TR?=	NV;UPIVEPzJiaB?=	MXTEUXNQ	MVHS[YR2[3Srb36gc4YheGyjc33hJI1mdWK{YX7lJIV5eHKnc4Ppc44hd2ZiQlPSVEBmgHC{ZYPzbY5oKHKncH;yeIVzKGenbnWgS2ZR	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF6NEKxN{c,OjRzOESyNVM9N2F-
BCRP-MDCK2	MWjGeY5kfGmxbjDBd5NigQ>?	M{LmWFEvQCEQvF2=	MlzCO\|IhcA>?	MlmxSG1UVw>?	MXzJcoNz\WG\|ZTDv[kBxdGG\|bXGgcYVu[nKjbnWg[ZhxemW\|c3nvckBw\iCEQ2LQJIV5eHKnc4PpcochemWyb4L0[ZIh\2WwZTDHSnA>	NVvDNIlWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxPFQzOTNpPkK0NVg1OjF\|PD;hQi=>
A431	NG\UeYZMcW6jc3WgRZN{[Xl?	MlK4NVAxKM7:TR?=	MVqzNEBucW5?		MYLJcohq[mm2aX;uJI9nKEWJRmKgbY4he2inZDDt[Y1jemGwZTD2[ZNq[2ynczD3bZRpKEmFNUCgc4YhOS5zIN88US=>	NXizWWF2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwPVQ1OzJpPkK0NFk1PDN{PD;hQi=>
HCC827	M3SxW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV6xNEDPxE1?	MYC3NkBp	MYnEUXNQ	MoT5RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDn[YZqfGmwaXKtd4Vve2m2aY\lJIh2dWGwIFjDR\|gzPyClZXzsd{Bp[XKkb4LpcochTUeIUjDFO\|Q3KHSxIFG3OVAh\GWuZYTpc44hf2m2aDDJR\|UxKG:oIECuNFA2QDFizszN	MmTOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyNUO2O\|QoRjJ2MEWzOlc1RC:jPh?=
HCC827	NEXEToNHfW6ldHnvckBCe3OjeR?=	NGfCPGMxNjVizszN	M{\kV\|IhcA>?	MlHISG1UVw>?	NVTD[oRsUW6qaXLpeIlwdiCxZjDjMW1mfCCyaH;zdIhwenmuYYTpc44hcW5iZ3XmbZRqdmmkLYLld4l{fGGwdDDoeY1idiCKQ1O4Nlch[2WubIO=	NWO4VIp1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5PVM{OjhpPkKzPVk{OzJ6PD;hQi=>
HCC827	NGHsfHNMcW6jc3WgRZN{[Xl?	M4O5b\|AvPSEQvF2=	MXGyJIg>	NF;FOoZFVVOR	MmW1TY5pcWKrdHnvckBw\iCHR1\SJJBpd3OyaH;yfYxifGmxbjDpckBo\W[rdHnubYIuemW\|aYP0ZY51KGi3bXHuJGhESzh{NzDj[Yxtew>?	NYnX[WV7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5PVM{OjhpPkKzPVk{OzJ6PD;hQi=>
A549	MmTRSpVv[3Srb36gRZN{[Xl?	NU\HWmxSOSEQvF2=	MnfZNUBp	MoTOSG1UVw>?	MV7D[YxtfWyjcjD1dJRic2V?	NITxZZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{m4PFM2PCd-MkO5PFg{PTR:L3G+
A549	NUnJfoxiU2mwYYPlJGF{e2G7	M2r4[FEh\|ryP	MnjVNUBp	M2Pm[mROW09?	NVjkWodUUW6qaXLpeIlwdiCxZjDFS2ZTKGG3dH;wbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFAvODN7OTFOwG0>	Mlv5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7OEizOVQoRjJ\|OUi4N\|U1RC:jPh?=
HCC827	NX;0T2o{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NV;HU4JQPzJiaB?=		NV7YOm1DUUN3ME2wMlAyOiEQvF2=	M{f2[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OUezNVY5Lz5{M{m3N\|E3QDxxYU6=
PC9	MX7LbY5ie2ViQYPzZZk>		MkDnNkBp	NUTzSGtuTE2VTx?=	Mn;hTY5pcWKrdHnvckBw\iCHR1\SJIV5d25iMUmg[IVt\XSrb36gZYN1cX[jdHnu[{BufXSjboSgdIhwe3Cqb4L5cIF1cW:wIHnuJIh2dWGwIGDDPUBk\WyuczD3bZRpKEmFNUCgc4YhOC5yMEi3JO69VQ>?	NUTuc5NuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5N\|A6QTRpPkKzPVMxQTl2PD;hQi=>
LoVo	MVPLbY5ie2ViQYPzZZk>		NHzDU2IzKCCq	M2nXPWROW09?	NH\Bc5lKdmirYnn0bY9vKG:oIFXHSnIheGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iByLkC2NkDPxE1?	MoLlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7M{C5PVQoRjJ\|OUOwPVk1RC:jPh?=
SH-SY5Y	MU\DfZRwfG:6aXOgRZN{[Xl?		M2\RV\|czKGh?		M4C4dmlEPTB;MUiuNlEh\|ryP	MmfhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6N{G5NFkoRjJ\|OEexPVA6RC:jPh?=
A549	M{jwTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1\TWFczKGh?	M3f6dWROW09?	M{Ta[mFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4Sge4lt\CC2eYDlJGVITlJxaz3SZZMh\GWyZX7k[Y51KGi3bXHuJGE2PDliY3XscJMhf2m2aDDJR\|UxKG:oIESuOlI3KM7:TR?=	Mn\XQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5OUKzNVgoRjJ\|N{myN\|E5RC:jPh?=
16HBE	NWXC[2k{TnWwY4Tpc44hSXO\|YYm=	NH;XXm8yODBizszN	MUCxOVAhdWmw	M1;QemROW09?	M4DwWmlv\HWldHnvckBw\iCwaYTybYMhd3irZHWgdJJw\HWldHnvckBqdiCqdX3hckAyPkiERTDj[YxteyCneIDy[ZN{cW6pIIfpcIQhfHmyZTDFS2ZT	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd7MkOxPEc,OjN5OUKzNVg9N2F-
16HBE	M1;Bb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Ml7IO\|IhcA>?	NYGyPIdFTE2VTx?=	MlnKRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiBzNljCSUBk\WyuczDlfJBz\XO\|aX7nJJdqdGRidInw[UBGT0[UIIfpeIghUUN3MDDv[kAyNjZyMTFOwG0>	Mm\QQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5OUKzNVgoRjJ\|N{myN\|E5RC:jPh?=
NCI-H1975	MnvDR5l1d3SxeHnjJGF{e2G7	Mn7xNVAh\|ryP	NIj3UWs4OiCq	MoLZSG1UVw>?	MlfHR5l1d3SxeHnjbZR6KGGpYXnud5Qh\2WoaYTpcoljNXKnc3nzeIFvfCCqdX3hckBPS0lvSEG5O\|Uh[2WubIOgbIFz[m:{aX7nJGVITlJiTEi1PHIwXDd7MF2g[I92[mynIH31eIFvfCCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjD3bZRpKEmFNUCgc4YhPi57MUeg{txO	NIjCSGY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[2PFQ1OSd-MkO2Olg1PDF:L3G+
16HBE14o-	NH3zTWlEgXSxdH;4bYMhSXO\|YYm=	MWSxNEDPxE1?	MWm3NkBp	NHzRTlFFVVOR	NIPhcZpEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckAyPkiERUG0c{0h[2WubIOgbIFz[m:{aX7nJJdqdGRidInw[UBGT0[UIHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJJdqfGhiSVO1NEBw\iBzMj63NUDPxE1?	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ4OES0NUc,OjN4Nki0OFE9N2F-
Sf9	MXzLbY5ie2ViQYPzZZk>		NXHqZWlqOSCq	MlfoSG1UVw>?	NGWwdGxKdmirYnn0bY9vKG:oIHj1cYFvKEeVVD30ZYdo\WRiRVfGVkBNQDN2UjDteZRidnRiZYjwdoV{e2WmIIfpeIghUUN3MDDv[kAxNjBzNTFOwG0>	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzMU[5NUc,OjN4MUG2PVE9N2F-
PC9	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml\HNVAh\|rypL33M	MUK3NkBp		M4TRO2lEPTB;MD6wNVQh\|ryP	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzFzNkG2PEc,OjNzMU[xOlg9N2F-
HCC827	M{TWSWN6fG:2b4jpZ{BCe3OjeR?=	NIDqNGcyOCEQvHevcWw>	NEHuVpQ4OiCq		NVjZO25sUUN3ME2wMlAxOTVizszN	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzFzNkG2PEc,OjNzMU[xOlg9N2F-
FADU	NVzSdJlsS3m2b4TvfIlkKEG\|c3H5	M{jzVVExKM7:Zz;tUC=>	MmPVO\|IhcA>?		MkXRTWM2OD1yLkC1JO69VQ>?	NVfpXoFXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOxNVYyPjhpPkKzNVE3OTZ6PD;hQi=>
Calu3	M2PCbWN6fG:2b4jpZ{BCe3OjeR?=	M2KySVExKM7:Zz;tUC=>	M4niTVczKGh?		NHv0SVFKSzVyPUGuOkDPxE1?	MnzYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNzMU[xOlgoRjJ\|MUG2NVY5RC:jPh?=
A498	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUniOJJnSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBOFk5KGOnbHzzJIV5eHKnc4PpcochTUeIUjDhcoQhW1KFIIfpeIghUUN3MDDv[kA5NjZizszN	NUHhdFI1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4NVg5PDhpPkKyPFE5QDR6PD;hQi=>
SGC7901	M{\1ZWN6fG:2b4jpZ{BCe3OjeR?=		M2HrOVczKGh?		NEHDNIJKSzVyPUGwMlI3KM7:TR?=	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjd{N{S0PUc,OjJ5Mke0OFk9N2F-
HT-29	MWnDfZRwfG:6aXOgRZN{[Xl?		NXjRZpl[PzJiaB?=		M4LZ[mlEPTB;Mz6zOkDPxE1?	NH75OGM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkeyO\|Q1QSd-MkK3Nlc1PDl:L3G+
H460	M3zZTWN6fG:2b4jpZ{BCe3OjeR?=		MW[3NkBp		M2DIRmlEPTB;NT61PUDPxE1?	M3n1dFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{N{K3OFQ6Lz5{MkeyO\|Q1QTxxYU6=
A431	NHfqToxMcW6jc3WgRZN{[Xl?	NITub48yODBizszN	MVuzNEBucW5?		MorzTY5pcWKrdHnvckBw\iCHR1\SJIRmemm4ZXSg[pJwdSCqdX3hckBCPDNzIHPlcIwhdWWvYoLhcoUh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBxd2y7LVfseU1VgXJicHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCxMlA5KM7:TR?=	M4\IclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{Nkm4O\|gzLz5{Mk[5PFc5OjxxYU6=
HCC827	MUDLbY5ie2ViQYPzZZk>	MXOwMlEzPSEQvF2=	MUWyOEBp	Mki3SG1UVw>?	NIW4UVdKdmirYnn0bY9vKG:oIFXHSnIh\GWuIFW3OFYuSTd3MDDteZRidnRvbXXkbYF1\WRiQXv0JJBpd3OyaH;yfYxifGmxbh?=	MoPDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{mzOFIoRjJ{M{O5N\|QzRC:jPh?=
HCC827	NVjwU4t5U2mwYYPlJGF{e2G7	MlK0NE4yOjVizszN	NHjJUHYzPCCq	NWP3VW9NTE2VTx?=	MUDJcohq[mm2aX;uJI9nKEWJRmKg[IVtKEV5NE[tRVc2OCCvdYThcpQudWWmaXH0[YQhTXKtIIDoc5NxcG:{eXzheIlwdg>?	Ml3NQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{mzOFIoRjJ{M{O5N\|QzRC:jPh?=
HCC827	NV\5TXI{U2mwYYPlJGF{e2G7	NEXDRWkxNjF{NTFOwG0>	MVOyOEBp	NHP4OGpFVVOR	M2i4U2lvcGmkaYTpc44hd2ZiRVfGVkBl\WxiRUe0Ok1CPzVyIH31eIFvfCC\MUC2PEBifXSxcHjvd5Bpd3K7bHH0bY9v	Mke5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{mzOFIoRjJ{M{O5N\|QzRC:jPh?=
MCF7	MnzwR5l1d3SxeHnjJGF{e2G7	NFzQdFEyOCEQvF2=	NEfVUZY1QCCq		MoHZR5l1d3SxeHnjbZR6KGGpYXnud5Qhe2W{dX2td5Rien[nZDDoeY1idiCPQ1[3JINmdGy\|IH;2[ZIu\XiycnXzd4lv\yCHcnLCNkBk\Wyucx?=	NFvsVWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkGzPFMxQCd-MkKxN\|g{ODh:L3G+
BT474	NX[yUWlnS3m2b4TvfIlkKEG\|c3H5	NF3tcHcyOCEQvF2=	MkPIOFghcA>?		MYXDfZRwfG:6aXPpeJkh[WejaX7zeEB{\XK3bT3zeIFzfmWmIHj1cYFvKEKWNEe0JINmdGy\|	NH;FZlU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkGzPFMxQCd-MkKxN\|g{ODh:L3G+
MCF7	M2f1Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHfZZ48yODEEoN88[{9uVA>?	M3npblQ5KGh?	MlH4SG1UVw>?	MX\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkegZ4VtdHNib4\ldoV5eHKnc4PpcochTUeIUjDn[Y5mKHerdHigTWM2OCCxZjCxNk4xPSEQvF2=	NHvtR3Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkGxPVE{OCd-MkKxNVkyOzB:L3G+
A431	NVvIdZZbU2mwYYPlJGF{e2G7		MVWyJIg>	MmPESG1UVw>?	NULOU2NXUW6qaXLpeIlwdiCxZjDFS2ZTKHCqb4PwbI9zgWyjdHnvckBqdiCHR1[td5RqdXWuYYTl[EBpfW2jbjDBOFMyKHerdHigTWM2OCCxZjCwMlAxOSEQvF2=	Ml7tQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzMEGxN\|IoRjJ{MUCxNVMzRC:jPh?=
NCI-H292	NXPTS5ByT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NEHjfW84OiCq	NYO0SGxXTE2VTx?=	MoPoTWM2OD1yLkCyJO69VQ>?	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTlzNkSzN{c,OjF7MU[0N\|M9N2F-
NCI-H1993	NV\sbmhjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3;nSFczKGh?	MmnFSG1UVw>?	MYPJR\|UxRTBwMTFOwG0>	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTlzNkSzN{c,OjF7MU[0N\|M9N2F-
Plasmodium falciparum					MX3xTHRUKHC{b3\pcIlv\yCob4KgbY5pcWKrdH;yd{Bw\iCSbHHzcY9lcXWvIH\hcINqeGG{dX2gdJJwdGmoZYLheIlwdg>?	NHf2SXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUixO\|A1PSd-MkG4NVcxPDV:L3G+
MDA-MB-468	MnvaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIPQV4YyODBizszN	M1zTelQ5KGh?	M2HXTGROW09?	MWPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eR?=	MlzyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF2Mkm2N\|IoRjJzNEK5OlMzRC:jPh?=
PC3	NWrQWYRbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHfzS3IyOCEQvF2=	NHnWNIY4OiCq	NVnSNoVPTE2VTx?=	MmjaTWM2OD15LkSg{txO	NIizPWc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUO1N\|U1Pid-MkGzOVM2PDZ:L3G+
PC9	NXHsRpJjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlrMRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDndo94fGhvcnXzbZN1[W62IHj1cYFvKFCFOTDj[YxteyCneIDy[ZN{cW6pIFXHSnIhTTd2Nm;BO\|UxN1R5OUDNJI12fGGwdDD3bZRpKEWFNUCgc4YhPyEQvF2=	NF\Zblc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUKwPFgxOid-MkGyNFg5ODJ:L3G+
PC9	M1y2dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3;IcWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgSWdHWi2mZX\pZ4lmdnRiaIXtZY4hWEN7IHPlcIx{KHerdHigSWM2OCCxZjCwMlAyPyEQvF2=	NGHhO4Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUKwPFgxOid-MkGyNFg5ODJ:L3G+
PANC1	M1;4eWN6fG:2b4jpZ{BCe3OjeR?=		NILo[2g2KGR?	NYCwWWRoTE2VTx?=	M1v6TWlEPTB;NECuOFIh\|ryP	NVjEWY1nRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC0OlY2PTVpPkKwOFY3PTV3PD;hQi=>
MIAPaCa2	MV7DfZRwfG:6aXOgRZN{[Xl?		NUL3dYdYPSCm	MkfmSG1UVw>?	MorVTWM2OD13MD62NkDPxE1?	M3v6WlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNE[2OVU2Lz5{MES2OlU2PTxxYU6=
DU145	MYjDfZRwfG:6aXOgRZN{[Xl?		M{LsdFUh\A>?	MoLGSG1UVw>?	MWTJR\|UxRTR{LkG3JO69VQ>?	NV3GbY9ORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC0OlY2PTVpPkKwOFY3PTV3PD;hQi=>
SMMC7721	MoTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MoD4OFghcA>?		M2W4[WlEPTB;M{OuNVIh\|ryP	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODNyNEWzO{c,OjB\|MES1N\|c9N2F-
A375	Mm\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MXu0PEBp		NGDSfW5KSzVyPUKwMlU2KM7:TR?=	NXLU[FBPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCzNFQ2OzdpPkKwN\|A1PTN5PD;hQi=>
NCI-H1975	Mo\uSpVv[3Srb36gRZN{[Xl?	NV;GbVBJPSEQvF2=	NWrrdphLPDhiaB?=		NIDkc4pKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHHzd4V{e2WmIHHzJIFkfGm4YYTpc44hd2ZiY3HzdIF{\S1\|	NEDlTFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEG1NVY4OCd-MkCxOVE3PzB:L3G+
NCI-H1975	Ml\USpVv[3Srb36gRZN{[Xl?	NUSwUWNuOTBizszN			MWPJcohq[mm2aX;uJI9nKEWUQlKyJIF2fG:yaH;zdIhwenmuYYTpc44>	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODF3MU[3NEc,OjBzNUG2O\|A9N2F-
NCI-H1975	MUXLbY5ie2ViQYPzZZk>	MUKxNEDPxE1?			NGPlbVBKdmirYnn0bY9vKG:oIFXHSnIh[XW2b4Doc5NxcG:{eXzheIlwdg>?	MnrHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzNUG2O\|AoRjJyMUWxOlcxRC:jPh?=
NCI-H1975	NYexboRZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV3RVYo6PSEQvF2=	NXnoWYxSPzJiaB?=		NHrhWZpKSzVyPUiuNlYh\|ryP	MlvVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzNUG2O\|AoRjJyMUWxOlcxRC:jPh?=
Sf9	MkjtT4lv[XOnIFHzd4F6		Mk\XNVAhdWmw	NWW0cVFNTE2VTx?=	MoHVTY5pcWKrdHnvckBw\iCHR1\SJIV5eHKnc4Pl[EBie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJJm[2WydH;yJIF2fG:yaH;zdIhwenmuYYTpc44hf2m2aDDJR\|UxKG:oIECuNFM{KM7:TR?=	NIXDToo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEC1OlQzPSd-MkCwOVY1OjV:L3G+
A431	NGXjfIRMcW6jc3WgRZN{[Xl?	NVnTNVJGOTByIN88US=>	M2LLVlExKG2rbh?=		MX7Qdo9td26pZXSgbY5pcWKrdH;yfUBi[3Srdnn0fUBw\iCHR1[tbY5lfWOnZDDFS2ZTKHCqb4PwbI9zgWyjdHnvci=>	M{jYW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OU[5OFY2Lz5zOUm2PVQ3PTxxYU6=
A431	MXfLbY5ie2ViQYPzZZk>	MV2wMlEh\|ryP	M1XDeFEhcA>?		NHHJ[29KdmirYnn0bY9vKG:oIFXHSk1qdmS3Y3XkJGVITlJicHjvd5Bpd3K7bHH0bY9v	NEH6clM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUm2PVQ3PSd-MUm5Olk1PjV:L3G+
A431	NXPOZ3ZKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3fwd\|ExKM7:TR?=	M3zlSVczKGh?		MoPtS2k2OD1yLkWxOEDPxE1?	NGLkR\|A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUm2PVQ3PSd-MUm5Olk1PjV:L3G+
MCF7 MX	M3rFTGZ2dmO2aX;uJGF{e2G7		M37JelMxKG2rbh?=		MVjJcohq[mm2aX;uJI9nKEKFUmCg[ZhxemW\|c3XkJJdqfGhiSVO1NEBw\iBzLkGg{txO	NGXsUJA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUmzNlk3OCd-MUm5N\|I6PjB:L3G+
NIH3T3	NWW2XGdUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MkfHO\|IhcA>?		NWXyd4pST3Kxd4ToJIlvcGmkaYTpc44hd2ZibX;1d4UhVkmKL{PUN{Bk\WyuczDlfJBz\XO\|aX7nJIVzSjJiZ3Xu[UB4cXSqIFnDOVAhd2ZiMD61OEDPxE1?	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTZ4NUO3O{c,OTl4NkWzO\|c9N2F-
BA/F3	NYH4OWhzS3m2b4TvfIlkKEG\|c3H5		NVO5SmxsPzJiaB?=		MXfDfZRwfG:6aXPpeJkh[WejaX7zeEBud3W\|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEWJRmKgUFg2QFJibYX0ZY51KHerdHigTWM2OCCxZjCwMlAyODhizszN	NGrPdWI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUKzPVIzQSd-MUmyN\|kzOjl:L3G+
HN5	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MV:3NkBp		NFHLfINCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjOOUBk\WyuczDveoVz\XiycnXzd4lv\yCHR1\SJJdqfGhiRVO1NEBw\iByLkCxJO69VQ>?	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTB{OESyOEc,OTlyMki0NlQ9N2F-
BT474	Ml;WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MoTvO\|IhcA>?		MlzkRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCEVES3OEBk\WyuczDveoVz\XiycnXzd4lv\yCHUlLiNkB4cXSqIFXDOVAhd2ZiMD6zJO69VQ>?	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTB{OESyOEc,OTlyMki0NlQ9N2F-
MCF7	NEXFXmtEgXSxdH;4bYMhSXO\|YYm=	M{DhcVUxKM7:TR?=	NIHPcHc4OiCq		NUTkOWp2UUN3ME2xNk4xPSEQvF2=	NHzPcoI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEe3NVgyQSd-MUi3O\|E5OTl:L3G+
MOLT4	Mom2R5l1d3SxeHnjJGF{e2G7		NHXjdHQ6PiCq	M2m3bGROW09?	NWTIbnNKUUN3ME2xOU4xOiEQvF2=	Ml22QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh\|MUO4NFcoRjF6M{GzPFA4RC:jPh?=
MDA-MB-231	NE\Lc4dEgXSxdH;4bYMhSXO\|YYm=		MkPYPVYhcA>?	Ml;uSG1UVw>?	MkP6TWM2OD1\|Nj62NUDPxE1?	MoTMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh\|MUO4NFcoRjF6M{GzPFA4RC:jPh?=
K562	MX3DfZRwfG:6aXOgRZN{[Xl?		NV;4RWpXQTZiaB?=	NWjRPWFUTE2VTx?=	M4XxR2lEPTB;OT6zOkDPxE1?	M4fsNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6M{GzPFA4Lz5zOEOxN\|gxPzxxYU6=
A549	MWPDfZRwfG:6aXOgRZN{[Xl?		NX31TJlSQTZiaB?=	NIHxXoFFVVOR	NWfCeW1mUUN3ME2xN{42QSEQvF2=	NHHLW249[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEOxN\|gxPyd-MUizNVM5ODd:L3G+
COS7	NVz1ZpR1TnWwY4Tpc44hSXO\|YYm=	M4K1cVk3KM7:TR?=			NH;0ZW1KdmirYnn0bY9vKG:oIHj1cYFvKEqDS{KgWlYyP0ZibYX0ZY51KGW6cILld5Nm\A>?	NIPNT3k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{G3PFczOid-MUexO\|g4OjJ:L3G+
NIH3T3	NV25RXZNTnWwY4Tpc44hSXO\|YYm=	MXSwMlIh\|ryP	MlLGNkBp	M13BbWROW09?	MUHJcohq[mm2aX;uJI9nKEWJRjDzeIlufWyjdHXkJIh2dWGwIHXyZmIyKGG3dH;wbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFAvODF2NDFOwG0>	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjR6MEK4OEc,OTZ2OECyPFQ9N2F-
KB	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4XrRmlEPTB;MD6wOVQh\|ryP	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjVzNkS3N{c,OTZ3MU[0O\|M9N2F-
GAK	NHXQTVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmS5TWM2OD1{MT60PVkh\|ryP	NFP4PWQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUe5OVc3Pyd-Mkm3PVU4Pjd:L3G+
SK-N-AS	M1vZ[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFfmTZNKSzVyPUKxMlU3OTlizszN	NYX2NotrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm2PVE{PDlpPkG5OlkyOzR7PD;hQi=>
OE33	NXnHeGhST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NITtcFdKSzVyPUKxMlYxPDZizszN	Mm[yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh2Nkm4NFkoRjF6NE[5PFA6RC:jPh?=
YKG-1	M1fwXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGXhUZFKSzVyPUKxMlY2PDVizszN	Mn6wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ7NESxNVkoRjJ{OUS0NVE6RC:jPh?=
CAL-85	MnPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoLwTWM2OD1{MT65N\|A2KM7:TR?=	NV;TNYF3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2N\|E{PTlpPkK0OlMyOzV7PD;hQi=>
NCI-H2347	M2rGTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFXFZ3dKSzVyPUKxMlk1OjhizszN	MkT0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{MkG3PVAoRjJ6MkKxO\|kxRC:jPh?=
PANC-08-13	NVT6WY0yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYD1e4JIUUN3ME2yNk4xOTF7IN88US=>	MmmyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{MkG3PVAoRjJ6MkKxO\|kxRC:jPh?=
SK-N-FI	NILKZm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmTHTWM2OD1{Mj6zNFc1KM7:TR?=	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDR4OUiwPUc,OTh2Nkm4NFk9N2F-
NEC8	MnjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4\JPGlEPTB;MkKuOVA4QCEQvF2=	NV;OemM2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK5OFQyOTlpPkKyPVQ1OTF7PD;hQi=>
AN3-CA	MlLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXjJR\|UxRTJ{Lk[wPFQh\|ryP	NWTDVXNjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK5OFQyOTlpPkKyPVQ1OTF7PD;hQi=>
HuO9	NIT5SINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWTkZWRwUUN3ME2yNk44Ozl4IN88US=>	NXzUT21oRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkewN\|I{OzFpPkK3NFMzOzNzPD;hQi=>
COLO-800	M1XrfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NILhN21KSzVyPUKyMlc3PTNizszN	NGnFR5M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO0NVM2Pid-MkSzOFE{PTZ:L3G+
HT-29	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWPzdFRVUUN3ME2yNk45QDJ\|IN88US=>	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTdzMUC1OEc,OjF5MUGwOVQ9N2F-
OC-314	NIf4VlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX34NZNOUUN3ME2yNk45QDR3IN88US=>	Mlj2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB6N{O3OFAoRjJyOEezO\|QxRC:jPh?=
G-401	M3rQfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MW\JR\|UxRTJ\|LkC0OlIh\|ryP	M3nscFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NE[5PFA6Lz5zOES2PVgxQTxxYU6=
Saos-2	NGS3RmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVnJR\|UxRTJ\|LkWxPFIh\|ryP	NFfNe3o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NES3NVk6QCd-MkS0O\|E6QTh:L3G+
UACC-62	MoizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4jMZmlEPTB;MkOuOVg{OyEQvF2=	MofHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl4OUGzOFkoRjF7NkmxN\|Q6RC:jPh?=
D-247MG	NHTaToVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGK2dpRKSzVyPUKzMlc6OzlizszN	NWPKVo1wRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi0Olk5ODlpPkG4OFY6QDB7PD;hQi=>
COLO-741	NVPldWdvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3;QPWlEPTB;MkOuPVU3PSEQvF2=	NHHT[Gc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEW4NFU2PCd-MkC1PFA2PTR:L3G+
ES3	Ml;US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV3JR\|UxRTJ2LkCwNlMh\|ryP	M3W0fFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkKxO\|kxLz5{OEKyNVc6ODxxYU6=
LNCaP-Clone-FGC	M1:xS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH7ONIdKSzVyPUK0MlAzOTFizszN	M4\PTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkKxO\|kxLz5{OEKyNVc6ODxxYU6=
SW1710	Mm\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXrJR\|UxRTJ2LkG1NFYh\|ryP	MoLjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyOUS5PVIoRjJ\|MEm0PVkzRC:jPh?=
LU-99A	M2fNfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUfVT25UUUN3ME2yOE4yQDRzIN88US=>	M4\DVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NkCyOFY1Lz5zN{[wNlQ3PDxxYU6=
HOP-92	NVTqOJZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWTOWGFTUUN3ME2yOE44OjVizszN	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR5MUm5PEc,OjR2N{G5PVg9N2F-
LS-123	NIfqcFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXLJR\|UxRTJ2Lkm2NVQh\|ryP	M3K4c\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{SyNVQ3Lz5{MkO0NlE1PjxxYU6=
T84	NUPaZ24xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3Pke2lEPTB;MkSuPVc3PSEQvF2=	NH3TeHU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUOyPFY2Pid-MkmzNlg3PTZ:L3G+
HCT-116	M3W2RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mny3TWM2OD1{NT60NVg3KM7:TR?=	Mn\zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2N{GxNVkoRjJ7NEexNVE6RC:jPh?=
M14	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4PwRWlEPTB;MkWuOFQ1PyEQvF2=	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzZyMkS2OEc,OTd4MEK0OlQ9N2F-
OCUB-M	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVjndHh4UUN3ME2yOU41PDV4IN88US=>	NUnCVpRURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3NVExPTRpPkKxO\|EyODV2PD;hQi=>
MKN45	NI\OeIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWL2cnRYUUN3ME2yOU43OzF3IN88US=>	NYryOXd6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wNlU5PzVpPkK2NFI2QDd3PD;hQi=>
LCLC-97TM1	M2e5WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXu0VnptUUN3ME2yOU44Ojh3IN88US=>	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDV6OEK4NUc,OTh3OEiyPFE9N2F-
RVH-421	M2XMO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVTJR\|UxRTJ3LkixOlEh\|ryP	NIfSflk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEi3N\|c1OCd-MkC4O\|M4PDB:L3G+
NKS-81-FD	M4\PTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVrJR\|UxRTJ3LkmwNlEh\|ryP	MmHKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{MkG3PVAoRjJ6MkKxO\|kxRC:jPh?=
NCI-H596	NX7HR\|VwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Moi1TWM2OD1{Nj6wOFg4KM7:TR?=	NUTRWWNwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3NFMzQTZpPkK1O\|A{Ojl4PD;hQi=>
GB-1	MnvyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{TEZWlEPTB;Mk[uNVg4QSEQvF2=	Ml;wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd4MEK0OlQoRjF5NkCyOFY1RC:jPh?=
ZR-75-30	NYLYcJBYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVnJR\|UxRTJ4LkKyPVch\|ryP	NFfnfWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{[wNlQ3PCd-MUe2NFI1PjR:L3G+
U-2-OS	NV6wZ\|NtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NG[zWlhKSzVyPUK2MlM4PTdizszN	M1[yclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{SyNVQ3Lz5{MkO0NlE1PjxxYU6=
HuP-T3	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVzJR\|UxRTJ4Lk[xNFIh\|ryP	MmHPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5MUGwOVQoRjJzN{GxNFU1RC:jPh?=
MOLT-16	M3PUeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVvJR\|UxRTJ4Lk[xOlYh\|ryP	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzZyMkS2OEc,OTd4MEK0OlQ9N2F-
U-87-MG	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2j0TGlEPTB;Mk[uO\|Q{QCEQvF2=	MnHVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl\|NkK0O\|QoRjF7M{[yOFc1RC:jPh?=
8505C	MljIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1jBVGlEPTB;Mk[uPVEzPiEQvF2=	NF\BNm89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEW4PFI5OSd-MUi1PFgzQDF:L3G+
SK-MEL-3	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2PFVWlEPTB;Mk[uPVgzQCEQvF2=	NELldmg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkO0NlE1Pid-MkKzOFIyPDZ:L3G+
COLO-824	NIfCb45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF\BfHJKSzVyPUK3MlIyQTVizszN	NHTC[\|Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[zNVM2QSd-MkS2N\|E{PTl:L3G+
EW-1	Ml\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXTJR\|UxRTJ5LkO1OVQh\|ryP	MmDZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl4NU[yNFIoRjJ7NkW2NlAzRC:jPh?=
UACC-257	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnzZTWM2OD1{Nz6zPFA1KM7:TR?=	MnnMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{MkG3PVAoRjJ6MkKxO\|kxRC:jPh?=
Hs-578-T	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXrtTnVrUUN3ME2yO{42Ojl7IN88US=>	MmDYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4M{GzOVkoRjJ2NkOxN\|U6RC:jPh?=
UACC-893	NVrPWIt2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4DEZ2lEPTB;MkeuOlY{OSEQvF2=	M4P6UlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{SyNVQ3Lz5{MkO0NlE1PjxxYU6=
MHH-NB-11	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVrJR\|UxRTJ5LkiwNFch\|ryP	Mk\aQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB6N{O3OFAoRjJyOEezO\|QxRC:jPh?=
KYSE-410	NY\GOZdFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{LyVGlEPTB;MkiuNlc4QSEQvF2=	M37BXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{GxNFU1Lz5{MUexNVA2PDxxYU6=
SF126	MlXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml\aTWM2OD1{OD63OFM2KM7:TR?=	MmjXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5MUGwOVQoRjJzN{GxNFU1RC:jPh?=
HT-144	MlXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml3JTWM2OD1{OT6zN\|YzKM7:TR?=	Mmr5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|NEKxOFYoRjJ{M{SyNVQ3RC:jPh?=
SW1573	MnXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3W3OWlEPTB;MkmuN\|UxQSEQvF2=	Ml\hQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyMkW4O\|UoRjJ4MEK1PFc2RC:jPh?=
SW620	NHf2S5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmjpTWM2OD1{OT6zOlQyKM7:TR?=	NUfSOHo2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiwO\|U2QTJpPkK4NFc2PTl{PD;hQi=>
SCH	NUHTSYxFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2XpeGlEPTB;MkmuPFg{OSEQvF2=	M1zaS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyOEezO\|QxLz5{MEi3N\|c1ODxxYU6=
EW-22	NUG2WY01T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX\JR\|UxRTNyLkG5Olkh\|ryP	MkTIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5MEOyPVYoRjJ3N{CzNlk3RC:jPh?=
H4	M4D0TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF6zcXhKSzVyPUOwMlQ3PTRizszN	MljGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyMkW4O\|UoRjJ4MEK1PFc2RC:jPh?=
CAS-1	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYDrN2FJUUN3ME2zNE44QDV7IN88US=>	NY\P[29pRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0O\|E6QThpPkK0OFcyQTl6PD;hQi=>
MG-63	M{e2R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{\zNWlEPTB;M{CuPFQ4QCEQvF2=	M3jSb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{GxNFU1Lz5{MUexNVA2PDxxYU6=
MDA-MB-415	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF;0Wm9KSzVyPUOxMlE4PTNizszN	M3zte\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NE[5PFA6Lz5zOES2PVgxQTxxYU6=
NCI-H1395	M1vLSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX7JR\|UxRTNzLkKzNlgh\|ryP	MoKxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl\|NkK0O\|QoRjF7M{[yOFc1RC:jPh?=
Ca-Ski	NXX1SplTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVLJR\|UxRTNzLkOxO\|ch\|ryP	MkTtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh2Nkm4NFkoRjF6NE[5PFA6RC:jPh?=
BxPC-3	NWjNWGVKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVHIWG1LUUN3ME2zNU4{PzJ7IN88US=>	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ\|MUO1PUc,OjR4M{GzOVk9N2F-
A3-KAW	M1Pyemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYDJR\|UxRTNzLkS0O\|Eh\|ryP	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzZyMkS2OEc,OTd4MEK0OlQ9N2F-
T-24	MmnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoP5TWM2OD1\|MT63N\|YzKM7:TR?=	NX[1W3RPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC1PFA2PTRpPkKwOVgxPTV2PD;hQi=>
NCI-H2029	NYnDZYdxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUHRUIJTUUN3ME2zNU44PzZ3IN88US=>	NGfHT5Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NES3NVk6QCd-MkS0O\|E6QTh:L3G+
YAPC	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3zyOWlEPTB;M{KuNFQxPyEQvF2=	M1;WTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{GxNFU1Lz5{MUexNVA2PDxxYU6=
SK-MEL-2	NG\UV2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWPINYVRUUN3ME2zNk4xPTJizszN	NY[5O2lWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmzOlI1PzRpPkG5N\|YzPDd2PD;hQi=>
LS-513	NGXYU5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIDIc21KSzVyPUOyMlEyQDdizszN	NW\pfmFMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmzOlI1PzRpPkG5N\|YzPDd2PD;hQi=>
AsPC-1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXvJR\|UxRTN{LkO2NFUh\|ryP	NWL0W5pwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUexNFE3PzRpPkG3NVAyPjd2PD;hQi=>
KYSE-150	NEG1PJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXXJR\|UxRTN{LkO3O\|Mh\|ryP	Mn7uQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{M{CxN\|EoRjJ\|MkOwNVMyRC:jPh?=
NCI-H520	NInSfW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mo\RTWM2OD1\|Mj60OFgzKM7:TR?=	NHruOoI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUexNVA2PCd-MkG3NVExPTR:L3G+
JEG-3	MkfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NULSTZFIUUN3ME2zN{4xQTdzIN88US=>	NFvkRXg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{KzNFE{OSd-MkOyN\|AyOzF:L3G+
GMS-10	M4[5bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1HiZ2lEPTB;M{OuN\|AxPCEQvF2=	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTdzMUC1OEc,OjF5MUGwOVQ9N2F-
HT-1080	M4\GWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1PETmlEPTB;M{OuN\|kh\|ryP	M1zMdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUm1OFY3Lz5{NEG5OVQ3PjxxYU6=
NCI-H1651	NF\WO\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3O4UWlEPTB;M{OuN\|k3KM7:TR?=	MlTvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl\|NkK0O\|QoRjF7M{[yOFc1RC:jPh?=
NCI-H2122	NWHRbIY3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYrJR\|UxRTN\|LkW1O\|Qh\|ryP	MlPMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB6N{O3OFAoRjJyOEezO\|QxRC:jPh?=
ES5	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYXNUGpGUUN3ME2zN{44Ojl{IN88US=>	NY[xWGFORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm2OVYzODJpPkK5OlU3OjB{PD;hQi=>
8305C	Ml;HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUHOZVhrUUN3ME2zN{46QTN5IN88US=>	NXTLXppXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmzOlI1PzRpPkG5N\|YzPDd2PD;hQi=>
KM12	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4TNe2lEPTB;M{SuNFQ4QCEQvF2=	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzJ\|MEGzNUc,OjN{M{CxN\|E9N2F-
HCT-15	MmjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2LQfWlEPTB;M{SuNVI4KM7:TR?=	M3;ndlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OU[4PFI1Lz5{M{m2PFgzPDxxYU6=
OVCAR-5	NYT6VHg3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1HQ[WlEPTB;M{SuNlE5OiEQvF2=	NGLPbGo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi2O\|U6OCd-MkS4Olc2QTB:L3G+
NCI-H2291	NFrs[JJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUjCO3IzUUN3ME2zOE4zPDd{IN88US=>	NHXiSlE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{KzNFE{OSd-MkOyN\|AyOzF:L3G+
CP50-MEL-B	NYTpNGRCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVLJR\|UxRTN2Lk[1PVIh\|ryP	MlKzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMEW3NlIoRjJ3MUC1O\|IzRC:jPh?=
C-33-A	MmHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmizTWM2OD1\|ND62PFU4KM7:TR?=	NHHufYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{m2Olk2OCd-Mke5OlY6PTB:L3G+
NCI-H2452	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{fwXWlEPTB;M{SuO\|g5OiEQvF2=	MlfyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5MUGwOVQoRjJzN{GxNFU1RC:jPh?=
MDA-MB-157	NH35UlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3jLSWlEPTB;M{SuPFE6OyEQvF2=	NGToOmk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUO2NlQ4PCd-MUmzOlI1PzR:L3G+
LN-405	NFyzUmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVvJR\|UxRTN3LkSzNFgh\|ryP	NIHPdHE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEi3N\|c1OCd-MkC4O\|M4PDB:L3G+
MDA-MB-231	NVXnbYNiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXzqXI9jUUN3ME2zOU42ODV2IN88US=>	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN4MEGwOEc,OjN\|NkCxNFQ9N2F-
EW-24	MmTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4jOPGlEPTB;M{WuOlM{PSEQvF2=	NWDmXo1nRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5Olg5OjRpPkKzPVY5QDJ2PD;hQi=>
MKN28	NWTJcFdpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWLJR\|UxRTN3LkiyN\|Yh\|ryP	MnPTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl\|NkK0O\|QoRjF7M{[yOFc1RC:jPh?=
KINGS-1	NEO3O4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{fxb2lEPTB;M{WuPFQ{PCEQvF2=	NUj2T5ljRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmzNlg3PTZpPkK5N\|I5PjV4PD;hQi=>
LC-2-ad	NHXwdWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF7xSHVKSzVyPUO2MlY6QSEQvF2=	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTdyM{K5Okc,OjV5MEOyPVY9N2F-
IGR-1	NHjHOmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHPGNIlKSzVyPUO2MlcxPzVizszN	NX;QbFJURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0N\|Y6QTRpPkK0OFM3QTl2PD;hQi=>
SW626	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4HD[GlEPTB;M{euNFQyPyEQvF2=	NFrNS\|Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkWxNlkxQCd-MkK1NVI6ODh:L3G+
ONS-76	M{\x[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX\JR\|UxRTN5LkGzNFkh\|ryP	NFzmN3g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{m2PFgzPCd-MkO5Olg5OjR:L3G+
T98G	M135c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1TlfGlEPTB;M{euPFY{PSEQvF2=	NHjFXVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUexNVA2PCd-MkG3NVExPTR:L3G+
NB14	NWLsRXRnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MljaTWM2OD1\|OD60OVQ1KM7:TR?=	NFziUoY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESzOlk6PCd-MkS0N\|Y6QTR:L3G+
D-423MG	NW\jNYF3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVSwVVNoUUN3ME2zPE41QDZ7IN88US=>	MoPIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl\|NkK0O\|QoRjF7M{[yOFc1RC:jPh?=
NCI-H510A	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmHhTWM2OD1\|OD62OFUyKM7:TR?=	M2[4cVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEm1NFgyLz5{OES5OVA5OTxxYU6=
NMC-G1	NWjOU\|FvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX7JR\|UxRTN6LkeyNlIh\|ryP	Ml;DQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5MUGwOVQoRjJzN{GxNFU1RC:jPh?=
SW948	MmPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUXJR\|UxRTN6Lki5OFkh\|ryP	NYD4WYdmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzOFE{PTZpPkK0N\|QyOzV4PD;hQi=>
MFM-223	NH3He2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1jCS2lEPTB;M{iuPVQ{OSEQvF2=	NF\kTWQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{SxPVYxPCd-MUe0NVk3ODR:L3G+
PAN1	MmfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUjmcWNbUUN3ME2zPE46QTF7IN88US=>	NYnJOVNpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK1NVI6ODhpPkKyOVEzQTB6PD;hQi=>
MZ7-mel	M4[4d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnvFTWM2OD1\|OT6xNVk6KM7:TR?=	MkLXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhyN{W1PVIoRjJ6MEe1OVkzRC:jPh?=
COLO-679	MlzoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFTHdYpKSzVyPUO5Mlk4ODhizszN	MlK0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5MUGwOVQoRjJzN{GxNFU1RC:jPh?=
SW872	Mnv4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2faPGlEPTB;NECuNlA{OSEQvF2=	NHPJRnQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[zNVM2QSd-MkS2N\|E{PTl:L3G+
HT-1197	NEfFfolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlTJTWM2OD12MD6yPFY6KM7:TR?=	M1vWflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5M{S5N\|MzLz5{N{O0PVM{OjxxYU6=
ES6	NVKwdZBwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkX0TWM2OD12MD60OVUzKM7:TR?=	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDF6Nk[wOEc,OThzOE[2NFQ9N2F-
SNU-387	MlK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX;F[GFDUUN3ME20NE45OjN6IN88US=>	NWnUSlhLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe0NVk3ODRpPkG3OFE6PjB2PD;hQi=>
T47D	NWDxcoJtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVLJR\|UxRTRzLkCxPVIh\|ryP	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDF6Nk[wOEc,OThzOE[2NFQ9N2F-
G-402	NHnIe\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYiwNlZGUUN3ME20NU4xQDB7IN88US=>	M3zXWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NEi5OlI3Lz5{M{S4PVYzPjxxYU6=
MZ1-PC	MlLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXz5TmRSUUN3ME20NU45OSEQvF2=	M3zuXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NkCyOFY1Lz5zN{[wNlQ3PDxxYU6=
SW1417	Ml23S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV;6dZo4UUN3ME20Nk4{ODNizszN	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzZyMkS2OEc,OTd4MEK0OlQ9N2F-
RERF-LC-MS	Ml2wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnjPTWM2OD12Mj61NFg4KM7:TR?=	M37BblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NUe2OlM{Lz5{OEW3OlY{OzxxYU6=
SF539	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkjuTWM2OD12Mj61OVI6KM7:TR?=	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR6OU[yOkc,OjN2OEm2NlY9N2F-
ESS-1	M4nhNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVTJR\|UxRTR\|LkW1OVgh\|ryP	Mkm5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh3N{[2N\|MoRjJ6NUe2OlM{RC:jPh?=
RO82-W-1	MkP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX;JR\|UxRTR\|Lk[xOVMh\|ryP	NIPoOVQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEW3OlY{Oyd-Mki1O\|Y3OzN:L3G+
S-117	MnjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2fPXmlEPTB;NEOuOlk2QCEQvF2=	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjVzMkmwPEc,OjJ3MUK5NFg9N2F-
SW756	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVTJR\|UxRTR\|LkiyOFIh\|ryP	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
CP66-MEL	NWLMWWs1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnPpTWM2OD12NT63NVQ{KM7:TR?=	M2q2d\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
H-EMC-SS	Mo\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXzaN41YUUN3ME20OU44Pjl\|IN88US=>	NIDoO4s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
NCI-H2052	NVrQSJpTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYHGR3AxUUN3ME20OU46ODJ5IN88US=>	MlvtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
SW684	NF2ycnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYfJR\|UxRTR5LkCwPFEh\|ryP	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
HCC1569	MkfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{DLOGlEPTB;NEeuNVY2QCEQvF2=	Mne4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
KGN	NETJN\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXvqTYRLUUN3ME20O{4{OzFzIN88US=>	M{n0bFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
LCLC-103H	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH\iNGlKSzVyPUS3MlQ1ODRizszN	M{\JflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
SW780	NYTyfYxmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4jS[2lEPTB;NEeuOlM2OSEQvF2=	MkDsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
NCI-H1703	MlLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXrtTmdpUUN3ME20PE4{OzV{IN88US=>	NFLGcFI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
HCC1395	MlO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX3JR\|UxRTR6Lke0N\|Ih\|ryP	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	phospho-EGFR / phospho-ERK / phospho-SRC / phospho-AKT; PubMed: 22586683 Cancer Discov Effect of overexpressing CRKL on phosphorylation levels of EGFR, ERK, AKT and SRC in response to gefitinib. HCC827 cells expressing a control vector or CRKL were exposed to gefitinib at indicated concentrations for 6 h and cell lysates were collected for immunoblotting with indicated specific antibodies. Cyclin D1/ p16 / p27 / pRb; PubMed: 18559346 J Biol Chem levels of phosphorylated and total EGFR, IGF-1R, Akt, ERK1/2, and Rb and levels of cyclin D1, p27, p16, and actin following 6- or 16-h treatment of A431 cells with combinations of 1 or 3 μm gefitinib and 3 μm NVP-ADW742. Data are representative of two independent experiments. uc-caspase-9 / c-caspase-9 / uc-caspase-3 / c-caspase-3 / uc-PARP / PARP; PubMed: 23102728 Mol Oncol Apoptosis resulting from combined treatment with gefitinib and an MEK inhibitor. (A) apoptosis relating protein induced by gefitinib and/or AZD6244 in PC‐9/wt and PC‐9/gef B4 cells. (B) Apoptosis relating protein induced by gefitinib and/or CI‐1040 in PC‐9/wt and PC‐9/gef B4 cells. (C) apoptosis relating protein induced by gefitinib and/or AZD6244 in PC‐9/gefE3 and PC‐9/gefE7 cells. (D) apoptosis relating protein induced by gefitinib and/or CI‐1040 in PC‐9/gefE3 and PC‐9/gefE7 cells. PPAR-γ; PubMed: 23409107 PLoS One Fold increase relative to control was determined after normalization with β-actin as external loading control.	22586683 18559346 23102728 23409107
Immunofluorescence	EGFR / LC3; PubMed: 31196210 J Exp Clin Cancer Res H157 and H1299 cells were treated with gefitinib, or curcumin alone, or gefitinib plus curcumin at indicated concentration for 48 h and then were fixed with methanol, immunostained with anti-EGFR (green), anti-LC3 (red), and DAPI (blue), and analyzed by confocal microscopy to determine the intracellular locations of EGFR and LC3. PPAR-γ; PubMed: 23409107 PLoS One Upregulation and nuclear accumulation of PPARγ following treatment with gefitinib (24 hs). p-EGFR / β-catenin; PubMed: 23461856 FEBS J In untreated CNE2 cells, β-catenin was located in cytoplasmic membranes and cytoplasm. Treatment with EGF (50 ng/mL) resulted in increased β-catenin nuclear staining, which was reversed by either gefitinib (1 μM) or LY294002 (15 μM).	31196210 23409107 23461856
Growth inhibition assay	GI50; PubMed: 23409107 PLoS One Dose-response of bladder cancer cell lines to EGFR inhibitor (gefitinib). The GI50 value was defined as the mean concentration of drug that generates 50% of growth inhibition as compared to controls.	23409107

In vivo

Gefitinib (100 mg/kg) improves the anti-tumor effect of radiotherapy in LoVo tumor xenografts. ^[3] Gefitinib treatment of nude mice bearing established human GEO colon cancer xenografts reveals a reversible dose-dependent inhibition of tumor growth because GEO tumors resumes the growth rate of controls at the end of the treatment. ^[4]

Protocol

Cell Research:

^[1]

- Collapse

Cell lines: NR6, NR6M and NR6W cells
Concentrations: 0-2 μM
Incubation Time: 72 hours
Method:
Exponentially growing cells including NR6, NR6M, NR6M and NR6W cells are seeded in sextuple in 96-well plates at a concentration of 2000 cells/well, allowed to adhere and subsequently washed in PBS and incubated overnight in medium containing 0.5% FCS. Cells are then treated with varying concentrations (0-2 μM) of Gefitinib or the solute control DMSO and EGF. The optimal EGF concentration for inducing proliferation of NR6wtEGFR and NR6W cells has previously been determined and hence NR6wtEGFR and NR6W cells are supplemented with 10 nM and 0.1 nM EGF, respectively. EGF is not added to NR6 and NR6M cells. After 72 hours the amount of cells are measured by performing a MTT proliferation assay.

(Only for Reference)

Animal Research:

^[3]

- Collapse

Animal Models: Female nude mice (cba nu/nu) aged 8–10 weeks are intra-dermal injected with LoVo cells.
Dosages: 100 mg/kg
Administration: Once daily by oral administration (0.1 mL/10 g body weight) for 14 days
(Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	89 mg/mL (199.14 mM)
	Ethanol	4 mg/mL (8.95 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 1% CMC Na For best results, use promptly after mixing.	30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Gefitinib (ZD1839) SDF

Molecular Weight	446.90
Formula	C₂₂H₂₄ClFN₄O₃
CAS No.	184475-35-2
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	Iressa
Smiles	COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03292133	Recruiting	Drug: EGF816\|Drug: Gefitinib	Lung Cancer	Massachusetts General Hospital\|Novartis	October 31 2017	Phase 2
NCT03122717	Active not recruiting	Drug: Gefitinib\|Drug: Osimertinib	Non-Small Cell Lung Cancer	Dana-Farber Cancer Institute\|AstraZeneca	May 9 2017	Phase 1\|Phase 2
NCT02932345	Completed	--	EGFR Mutation Positive Advanced Non-small-cell Lung Cancer	AstraZeneca	October 31 2016	--
NCT02824458	Recruiting	Drug: Apatinib\|Drug: Gefitinib\|Drug: Placebo	EGFR Tyrosine Kinase Inhibitors Plus VEGFR Inhibitors	Sun Yat-sen University	June 2016	Phase 3
NCT02804100	Unknown status	--	Carcinoma Non-Small-Cell Lung\|Bronchial Neoplasms\|Carcinoma Bronchogenic\|Lung Diseases\|Lung Neoplasms	Wenzhou Medical University	May 2016	--

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I try to dissolve Gefitinib (ZD1839) in 0.5% methylcellulose+0.2% Tween 80 for in vivo experiments. However, when I prepare the mixture, it forms precipitates. Exists another way to dissolve completely the compound?
Answer:
S1025 can be dissovled in both 5% DMSO+corn oil and 5% DMSO+30% PEG 300+5% Tween 80+ddH2O at 2.5 mg/ml clearly. It dissolves in DMSO not readily, please sonicate and warm it in water bath at about 45 degree, and dissolve it clearly first. Then add other solvent.

EGFR Signaling Pathway Map

EGFR Inhibitors with Unique Features

Pan EGFR Inhibitor

AZD8931 (Sapitinib) : Pan-ErbB inhibitor, EGFR/ErbB2/ErbB3, IC50=4 nM/3 nM/4 nM.
Most Potent EGFR Inhibitor

Afatinib (BIBW2992) : EGFR(wt), IC50=0.5 nM; EGFR(L858R), IC50=0.4 nM; EGFR(L858R/T790M), IC50=10 nM; HER2, IC50=14 nM.
FDA-approved EGFR Inhibitor

Lapatinib : Approved by FDA for breast cancer.
Newest EGFR Inhibitor

CO-1686 (AVL-301) ^New : Irreversible, mutant-selective EGFR inhibitor with K_i of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT, respectively.

Related EGFR Products

Erlotinib ^New

Erlotinib (CP358774, NSC 718781, OSI-774) is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. Erlotinib induces autophagy.
Afatinib (BIBW2992) Dimaleate ^New

Afatinib (BIBW2992) Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant. Afatinib (BIBW2992) Dimaleate induces autophagy.
Poziotinib (HM781-36B) ^New

Poziotinib (HM781-36B, NOV120101) is an irreversible pan-HER inhibitor with IC50 of 3.2 nM, 5.3 nM and 23.5 nM for HER1, HER2, and HER4, respectively. Poziotinib also induces apoptosis and G1 cell cycle arrest. Phase 2.
Erlotinib HCl (OSI-744)

Erlotinib HCl (OSI-744, CP358774, NSC 718781) is an EGFR inhibitor with IC50 of 2 nM in cell-free assays, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.
Afatinib (BIBW2992)

Afatinib (BIBW2992) inhibits EGFR/ErbB irreversibly in vitro with IC50 of 0.5, 0.4, 10, 14, 1 nM for EGFR^wt, EGFR^L858R, EGFR^L858R/T790M ErbB2 (HER2) and ErbB4 (HER4), respectively. Afatinib induces autophagy.
Osimertinib (AZD9291)

Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.
Lapatinib (GW-572016)

Lapatinib (GW-572016, GSK572016, GW2016), used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively. Lapatinib induces ferroptosis and autophagic cell death.
AG-490 (Tyrphostin B42)

AG-490 (Tyrphostin B42, Zinc02557947) is an inhibitor of EGFR with IC50 of 0.1 μM in cell-free assays, 135-fold more selective for EGFR versus ErbB2, also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src.
Rociletinib (CO-1686)

Rociletinib (CO-1686, AVL-301) is an irreversible, mutant-selective EGFR inhibitor with K_i of 21.5 nM and 303.3 nM for EGFR^L858R/T790M and EGFR^WT in cell-free assays, respectively. Phase 2.
AG-1478 (Tyrphostin AG-1478)

AG-1478 (Tyrphostin AG-1478, NSC 693255) is a selective EGFR inhibitor with IC50 of 3 nM in cell-free assays, almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR. AG-1478 (Tyrphostin AG-1478) inhibits encephalomyocarditis virus (EMCV) and hepatitis c virus (HCV) by targeting phosphatidylinositol 4-kinase IIIα (PI4KA).

Choose Your Country or Region

By Signaling Pathways

By product type

Gefitinib (ZD1839)